(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB00526'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB00544'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
NsS'contraindication'
p11
NsS'researchStatementLabel'
p12
NsS'severity'
p13
NsS'label'
p14
NsS'effectConcept'
p15
NsS'source'
p16
S'DDI-Corpus-2013'
p17
sS'ddiPkEffect'
p18
NsS'evidenceType'
p19
NsS'homepage'
p20
NsS'pathway'
p21
NsS'ddiType'
p22
S'mechanism'
p23
sS'researchStatement'
p24
NsS'dateAnnotated'
p25
NsS'object'
p26
S'\xef\xbb\xbf5-FU'
p27
sS'evidenceSource'
p28
NsS'evidenceStatement'
p29
S'Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. | \r'
p30
sS'precipUri'
p31
NsS'certainty'
p32
NsS'uri'
p33
NsS'precip'
p34
NsS'numericVal'
p35
NsS'precaution'
p36
NsS'precipitant'
p37
S'Eloxatin'
p38
sa(dp39
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p40
sg5
S'http://bio2rdf.org/drugbank:DB01238'
p41
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p42
sg24
Nsg25
Nsg26
S'Abilify'
p43
sg28
Nsg29
S'Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.| \r'
p44
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p45
sa(dp46
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p47
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p48
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p49
sg24
Nsg25
Nsg26
S'ACETAZOLAMIDE'
p50
sg28
Nsg29
S'Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.| \r'
p51
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SODIUM BICARBONATE'
p52
sa(dp53
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p54
sg5
S'http://bio2rdf.org/drugbank:DB03128'
p55
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p56
sg24
Nsg25
Nsg26
S'Acetylcholine Chloride'
p57
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p58
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p59
sa(dp60
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00166'
p61
sg5
S'http://bio2rdf.org/drugbank:DB08842'
p62
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p63
sg24
Nsg25
Nsg26
S'acetyl-L-carnitine'
p64
sg28
Nsg29
S'(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.| \r'
p65
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'alpha-Lipoic acid'
p66
sa(dp67
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01016'
p68
sg5
S'http://bio2rdf.org/drugbank:DB00459'
p69
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p70
sg24
Nsg25
Nsg26
S'ACITRETIN'
p71
sg28
Nsg29
S'Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| \r'
p72
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Glibenclamide'
p73
sa(dp74
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p75
sg5
S'http://bio2rdf.org/drugbank:DB01285'
p76
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p77
sg24
Nsg25
Nsg26
S'ACTH'
p78
sg28
Nsg29
S'Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.| \r'
p79
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p80
sa(dp81
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01159'
p82
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p83
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p84
sg24
Nsg25
Nsg26
S'Adrenaline'
p85
sg28
Nsg29
S'Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| \r'
p86
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fluothane'
p87
sa(dp88
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p89
sg5
S'http://bio2rdf.org/drugbank:DB00775'
p90
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p91
sg24
Nsg25
Nsg26
S'Aggrastat'
p92
sg28
Nsg29
S'The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see| \r'
p93
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p94
sa(dp95
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p96
sg5
S'http://bio2rdf.org/drugbank:DB00810'
p97
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p98
sg24
Nsg25
Nsg26
S'Akineton'
p99
sg28
Nsg29
S'Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| \r'
p100
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEPERIDINE'
p101
sa(dp102
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p103
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p104
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p105
sg24
Nsg25
Nsg26
S'Alcohol'
p106
sg28
Nsg29
S'As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| \r'
p107
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Abilify'
p108
sa(dp109
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p110
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p111
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p112
sg24
Nsg25
Nsg26
S'Alcohol'
p113
sg28
Nsg29
S'Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| \r'
p114
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p115
sa(dp116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00327'
p117
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p119
sg24
Nsg25
Nsg26
S'Alcohol'
p120
sg28
Nsg29
S'Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.| \r'
p121
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dilaudid'
p122
sa(dp123
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p124
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p125
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p126
sg24
Nsg25
Nsg26
S'Alcohol'
p127
sg28
Nsg29
S'Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| \r'
p128
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lexapro'
p129
sa(dp130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01107'
p131
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p133
sg24
Nsg25
Nsg26
S'Alcohol'
p134
sg28
Nsg29
S'Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.| \r'
p135
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Methyprylon'
p136
sa(dp137
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p138
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p139
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p140
sg24
Nsg25
Nsg26
S'Alcohol'
p141
sg28
Nsg29
S'Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.| \r'
p142
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pentazocine'
p143
sa(dp144
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01142'
p145
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p146
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p147
sg24
Nsg25
Nsg26
S'Alcohol'
p148
sg28
Nsg29
S'Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.| \r'
p149
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sinequan'
p150
sa(dp151
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p152
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p153
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p154
sg24
Nsg25
Nsg26
S'Alcohol'
p155
sg28
Nsg29
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p156
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p157
sa(dp158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p159
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p161
sg24
Nsg25
Nsg26
S'Alcohol'
p162
sg28
Nsg29
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p163
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Wellbutrin'
p164
sa(dp165
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p166
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p167
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p168
sg24
Nsg25
Nsg26
S'Alcohol'
p169
sg28
Nsg29
S'Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p170
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Wellbutrin'
p171
sa(dp172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p173
sg5
S'http://bio2rdf.org/drugbank:DB00950'
p174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p175
sg24
Nsg25
Nsg26
S'Allegra'
p176
sg28
Nsg29
S'ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| \r'
p177
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p178
sa(dp179
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p180
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p181
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p182
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p183
sg28
Nsg29
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p184
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p185
sa(dp186
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p187
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p188
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p189
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p190
sg28
Nsg29
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p191
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORPROPAMIDE'
p192
sa(dp193
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p194
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p195
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p196
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p197
sg28
Nsg29
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p198
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORPROPAMIDE'
p199
sa(dp200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p201
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p203
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p204
sg28
Nsg29
S'Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.| \r'
p205
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dicumarol'
p206
sa(dp207
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p208
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p209
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p210
sg24
Nsg25
Nsg26
S'ALLOPURINOL'
p211
sg28
Nsg29
S'Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| \r'
p212
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p213
sa(dp214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p215
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p217
sg24
Nsg25
Nsg26
S'ALMOTRIPTAN'
p218
sg28
Nsg29
S'Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| \r'
p219
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p220
sa(dp221
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p222
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p223
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p224
sg24
Nsg25
Nsg26
S'ALMOTRIPTAN'
p225
sg28
Nsg29
S'Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| \r'
p226
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p227
sa(dp228
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p229
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p230
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p231
sg24
Nsg25
Nsg26
S'ALOSETRON'
p232
sg28
Nsg29
S'Concomitant administration of alosetron and fluvoxamine is contraindicated.| \r'
p233
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p234
sa(dp235
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p236
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p237
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p238
sg24
Nsg25
Nsg26
S'ALOSETRON'
p239
sg28
Nsg29
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p240
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDRALAZINE'
p241
sa(dp242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p243
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p245
sg24
Nsg25
Nsg26
S'ALOSETRON'
p246
sg28
Nsg29
S'Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| \r'
p247
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p248
sa(dp249
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p250
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p251
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p252
sg24
Nsg25
Nsg26
S'ALOSETRON'
p253
sg28
Nsg29
S'Caution should be used when alosetron and ketoconazole are administered concomitantly.| \r'
p254
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p255
sa(dp256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p257
sg5
S'http://bio2rdf.org/drugbank:DB00969'
p258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p259
sg24
Nsg25
Nsg26
S'ALOSETRON'
p260
sg28
Nsg29
S'Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| \r'
p261
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VORICONAZOLE'
p262
sa(dp263
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p264
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p265
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p266
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p267
sg28
Nsg29
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p268
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p269
sa(dp270
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p271
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p272
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p273
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p274
sg28
Nsg29
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p275
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p276
sa(dp277
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p278
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p279
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p280
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p281
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p282
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p283
sa(dp284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p285
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p287
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p288
sg28
Nsg29
S'Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| \r'
p289
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERGOTAMINE'
p290
sa(dp291
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p292
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p293
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p294
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p295
sg28
Nsg29
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p296
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p297
sa(dp298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p299
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p301
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p302
sg28
Nsg29
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p303
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p304
sa(dp305
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p306
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p307
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p308
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p309
sg28
Nsg29
S'This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p310
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p311
sa(dp312
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p313
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p314
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p315
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p316
sg28
Nsg29
S'Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| \r'
p317
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p318
sa(dp319
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p320
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p321
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p322
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p323
sg28
Nsg29
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p324
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p325
sa(dp326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p327
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p329
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p330
sg28
Nsg29
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p331
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p332
sa(dp333
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p334
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p335
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p336
sg24
Nsg25
Nsg26
S'ALPRAZOLAM'
p337
sg28
Nsg29
S'Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| \r'
p338
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p339
sa(dp340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p341
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p343
sg24
Nsg25
Nsg26
S'ALUMINUM HYDROXIDE'
p344
sg28
Nsg29
S'Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| \r'
p345
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p346
sa(dp347
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p348
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p349
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p350
sg24
Nsg25
Nsg26
S'ALUMINUM'
p351
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p352
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p353
sa(dp354
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p355
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p356
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p357
sg24
Nsg25
Nsg26
S'ALUMINUM'
p358
sg28
Nsg29
S'The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | \r'
p359
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Skelid'
p360
sa(dp361
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p362
sg5
S'http://bio2rdf.org/drugbank:DB01370'
p363
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p364
sg24
Nsg25
Nsg26
S'ALUMINUM'
p365
sg28
Nsg29
S'Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| \r'
p366
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p367
sa(dp368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p369
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p371
sg24
Nsg25
Nsg26
S'AMINOSALICYLIC ACID'
p372
sg28
Nsg29
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p373
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p374
sa(dp375
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p376
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p377
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p378
sg24
Nsg25
Nsg26
S'AMINOSALICYLIC ACID'
p379
sg28
Nsg29
S'Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| \r'
p380
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lanoxin'
p381
sa(dp382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p383
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p385
sg24
Nsg25
Nsg26
S'AMINOSALICYLIC ACID'
p386
sg28
Nsg29
S'Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.| \r'
p387
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p388
sa(dp389
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p390
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p391
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p392
sg24
Nsg25
Nsg26
S'AMIODARONE'
p393
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| Amiodarone is known to raise serum digoxin levels. | During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). | \r'
p394
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p395
sa(dp396
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p397
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p398
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p399
sg24
Nsg25
Nsg26
S'AMIODARONE'
p400
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p401
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p402
sa(dp403
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p404
sg5
S'http://bio2rdf.org/drugbank:DB00321'
p405
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p406
sg24
Nsg25
Nsg26
S'AMITRIPTYLINE'
p407
sg28
Nsg29
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p408
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONIDINE'
p409
sa(dp410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p411
sg5
S'http://bio2rdf.org/drugbank:DB01060'
p412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p413
sg24
Nsg25
Nsg26
S'AMOXICILLIN ANHYDROUS'
p414
sg28
Nsg29
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p415
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p416
sa(dp417
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p418
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p419
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p420
sg24
Nsg25
Nsg26
S'AMPHOTERICIN B'
p421
sg28
Nsg29
S'Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.| \r'
p422
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCYTOSINE'
p423
sa(dp424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00741'
p425
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p427
sg24
Nsg25
Nsg26
S'AMPHOTERICIN B'
p428
sg28
Nsg29
S'In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| \r'
p429
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDROCORTISONE'
p430
sa(dp431
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p432
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p433
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p434
sg24
Nsg25
Nsg26
S'AMPHOTERICIN B'
p435
sg28
Nsg29
S'Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).| \r'
p436
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TUBOCURARINE'
p437
sa(dp438
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p439
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p440
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p441
sg24
Nsg25
Nsg26
S'Amphotericin'
p442
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p443
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p444
sa(dp445
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p446
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p447
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p448
sg24
Nsg25
Nsg26
S'Amphotericin'
p449
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p450
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p451
sa(dp452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p453
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p455
sg24
Nsg25
Nsg26
S'AMPICILLIN'
p456
sg28
Nsg29
S'It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p457
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p458
sa(dp459
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p460
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p461
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p462
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p463
sg28
Nsg29
S'Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | \r'
p464
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p465
sa(dp466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p467
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p469
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p470
sg28
Nsg29
S'Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | \r'
p471
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p472
sa(dp473
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p474
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p475
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p476
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p477
sg28
Nsg29
S'Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| \r'
p478
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p479
sa(dp480
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p481
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p482
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p483
sg24
Nsg25
Nsg26
S'AMPRENAVIR'
p484
sg28
Nsg29
S'Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| \r'
p485
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p486
sa(dp487
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p488
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p489
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p490
sg24
Nsg25
Nsg26
S'Anafranil'
p491
sg28
Nsg29
S'Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| \r'
p492
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p493
sa(dp494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p495
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p497
sg24
Nsg25
Nsg26
S'ANAGRELIDE'
p498
sg28
Nsg29
S'Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| \r'
p499
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p500
sa(dp501
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p502
sg5
S'http://bio2rdf.org/drugbank:DB01217'
p503
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p504
sg24
Nsg25
Nsg26
S'ANASTROZOLE'
p505
sg28
Nsg29
S'Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| \r'
p506
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tamoxifen'
p507
sa(dp508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p509
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p511
sg24
Nsg25
Nsg26
S'Antizol'
p512
sg28
Nsg29
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p513
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p514
sa(dp515
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p516
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p517
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p518
sg24
Nsg25
Nsg26
S'APOMORPHINE'
p519
sg28
Nsg29
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p520
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALOSETRON'
p521
sa(dp522
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00757'
p523
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p524
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p525
sg24
Nsg25
Nsg26
S'APOMORPHINE'
p526
sg28
Nsg29
S'5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p527
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dolasetron'
p528
sa(dp529
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p530
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p531
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p532
sg24
Nsg25
Nsg26
S'APREPITANT'
p533
sg28
Nsg29
S'therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p534
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p535
sa(dp536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p537
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p539
sg24
Nsg25
Nsg26
S'APREPITANT'
p540
sg28
Nsg29
S'Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| \r'
p541
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p542
sa(dp543
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p544
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p545
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p546
sg24
Nsg25
Nsg26
S'APREPITANT'
p547
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| \r'
p548
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p549
sa(dp550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p551
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p553
sg24
Nsg25
Nsg26
S'APREPITANT'
p554
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| \r'
p555
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p556
sa(dp557
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p558
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p559
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p560
sg24
Nsg25
Nsg26
S'APREPITANT'
p561
sg28
Nsg29
S'Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| \r'
p562
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p563
sa(dp564
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p565
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p566
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p567
sg24
Nsg25
Nsg26
S'APREPITANT'
p568
sg28
Nsg29
S'Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| \r'
p569
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p570
sa(dp571
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p572
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p573
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p574
sg24
Nsg25
Nsg26
S'APREPITANT'
p575
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p576
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p577
sa(dp578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p579
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p581
sg24
Nsg25
Nsg26
S'APREPITANT'
p582
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p583
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p584
sa(dp585
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p586
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p587
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p588
sg24
Nsg25
Nsg26
S'APREPITANT'
p589
sg28
Nsg29
S'Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| \r'
p590
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORETHINDRONE'
p591
sa(dp592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p593
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p595
sg24
Nsg25
Nsg26
S'APREPITANT'
p596
sg28
Nsg29
S'Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.| \r'
p597
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p598
sa(dp599
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p600
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p601
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p602
sg24
Nsg25
Nsg26
S'APREPITANT'
p603
sg28
Nsg29
S'Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| \r'
p604
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p605
sa(dp606
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p607
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p608
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p609
sg24
Nsg25
Nsg26
S'APREPITANT'
p610
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p611
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p612
sa(dp613
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p614
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p615
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p616
sg24
Nsg25
Nsg26
S'APREPITANT'
p617
sg28
Nsg29
S'Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.| \r'
p618
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p619
sa(dp620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p621
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p623
sg24
Nsg25
Nsg26
S'APREPITANT'
p624
sg28
Nsg29
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p625
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p626
sa(dp627
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p628
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p629
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p630
sg24
Nsg25
Nsg26
S'Arava'
p631
sg28
Nsg29
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p632
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p633
sa(dp634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p635
sg5
S'http://bio2rdf.org/drugbank:DB01097'
p636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p637
sg24
Nsg25
Nsg26
S'Arava'
p638
sg28
Nsg29
S'Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| \r'
p639
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p640
sa(dp641
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p642
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p643
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p644
sg24
Nsg25
Nsg26
S'Aspirin'
p645
sg28
Nsg29
S'However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| \r'
p646
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celebrex'
p647
sa(dp648
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01399'
p649
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p650
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p651
sg24
Nsg25
Nsg26
S'Aspirin'
p652
sg28
Nsg29
S'ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. | \r'
p653
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Disalcid'
p654
sa(dp655
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p656
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p657
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p658
sg24
Nsg25
Nsg26
S'Aspirin'
p659
sg28
Nsg29
S'The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| \r'
p660
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fenoprofen'
p661
sa(dp662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00712'
p663
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p665
sg24
Nsg25
Nsg26
S'Aspirin'
p666
sg28
Nsg29
S'Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.| \r'
p667
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Flurbiprofen'
p668
sa(dp669
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p670
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p671
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p672
sg24
Nsg25
Nsg26
S'Aspirin'
p673
sg28
Nsg29
S'Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. | \r'
p674
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Meloxicam'
p675
sa(dp676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00703'
p677
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p679
sg24
Nsg25
Nsg26
S'Aspirin'
p680
sg28
Nsg29
S'Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.| \r'
p681
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Methazolamide'
p682
sa(dp683
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p684
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p685
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p686
sg24
Nsg25
Nsg26
S'Aspirin'
p687
sg28
Nsg29
S'Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. | \r'
p688
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mobic'
p689
sa(dp690
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p691
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p692
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p693
sg24
Nsg25
Nsg26
S'Aspirin'
p694
sg28
Nsg29
S'Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| \r'
p695
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nalfon'
p696
sa(dp697
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00627'
p698
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p699
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p700
sg24
Nsg25
Nsg26
S'Aspirin'
p701
sg28
Nsg29
S'Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| \r'
p702
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nicotinic Acid'
p703
sa(dp704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00585'
p705
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p707
sg24
Nsg25
Nsg26
S'Aspirin'
p708
sg28
Nsg29
S'In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| \r'
p709
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nizatidine'
p710
sa(dp711
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p712
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p713
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p714
sg24
Nsg25
Nsg26
S'Aspirin'
p715
sg28
Nsg29
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p716
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p717
sa(dp718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p719
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p721
sg24
Nsg25
Nsg26
S'Aspirin'
p722
sg28
Nsg29
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p723
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p724
sa(dp725
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00015'
p726
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p727
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p728
sg24
Nsg25
Nsg26
S'Aspirin'
p729
sg28
Nsg29
S'In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| \r'
p730
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Retavase'
p731
sa(dp732
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01133'
p733
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p734
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p735
sg24
Nsg25
Nsg26
S'Aspirin'
p736
sg28
Nsg29
S'Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. | \r'
p737
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Skelid'
p738
sa(dp739
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p740
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p741
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p742
sg24
Nsg25
Nsg26
S'Aspirin'
p743
sg28
Nsg29
S'Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| \r'
p744
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p745
sa(dp746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p747
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p749
sg24
Nsg25
Nsg26
S'Aspirin'
p750
sg28
Nsg29
S'Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| \r'
p751
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vioxx'
p752
sa(dp753
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p754
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p755
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p756
sg24
Nsg25
Nsg26
S'ASTEMIZOLE'
p757
sg28
Nsg29
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p758
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p759
sa(dp760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p761
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p763
sg24
Nsg25
Nsg26
S'ASTEMIZOLE'
p764
sg28
Nsg29
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p765
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p766
sa(dp767
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p768
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p769
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p770
sg24
Nsg25
Nsg26
S'ASTEMIZOLE'
p771
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p772
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p773
sa(dp774
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p775
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p776
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p777
sg24
Nsg25
Nsg26
S'Atromid-S'
p778
sg28
Nsg29
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p779
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p780
sa(dp781
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p782
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p783
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p784
sg24
Nsg25
Nsg26
S'Atropine'
p785
sg28
Nsg29
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p786
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRALIDOXIME'
p787
sa(dp788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00733'
p789
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p791
sg24
Nsg25
Nsg26
S'Atropine'
p792
sg28
Nsg29
S'The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p793
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRALIDOXIME'
p794
sa(dp795
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00427'
p796
sg5
S'http://bio2rdf.org/drugbank:DB00572'
p797
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p798
sg24
Nsg25
Nsg26
S'Atropine'
p799
sg28
Nsg29
S'The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. | \r'
p800
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIPROLIDINE'
p801
sa(dp802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p803
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p805
sg24
Nsg25
Nsg26
S'AURANOFIN'
p806
sg28
Nsg29
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p807
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cuprimine'
p808
sa(dp809
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p810
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p811
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p812
sg24
Nsg25
Nsg26
S'AURANOFIN'
p813
sg28
Nsg29
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p814
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Depen'
p815
sa(dp816
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00108'
p817
sg5
S'http://bio2rdf.org/drugbank:DB00060'
p818
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p819
sg24
Nsg25
Nsg26
S'Avonex'
p820
sg28
Nsg29
S'After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.| \r'
p821
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tysabri'
p822
sa(dp823
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p824
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p825
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p826
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p827
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p828
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Amikacin'
p829
sa(dp830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p831
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p833
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p834
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p835
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p836
sa(dp837
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p838
sg5
S'http://bio2rdf.org/drugbank:DB01061'
p839
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p840
sg24
Nsg25
Nsg26
S'AZLOCILLIN'
p841
sg28
Nsg29
S'Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| \r'
p842
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOBRAMYCIN'
p843
sa(dp844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01086'
p845
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p847
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p848
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p849
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BENZOCAINE'
p850
sa(dp851
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p852
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p853
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p854
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p855
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p856
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORAMPHENICOL'
p857
sa(dp858
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00446'
p859
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p860
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p861
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p862
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p863
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Chloromycetin'
p864
sa(dp865
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01035'
p866
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p867
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p868
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p869
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p870
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pronestyl'
p871
sa(dp872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p873
sg5
S'http://bio2rdf.org/drugbank:DB00522'
p874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p875
sg24
Nsg25
Nsg26
S'BENTIROMIDE'
p876
sg28
Nsg29
S'Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| \r'
p877
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tylenol'
p878
sa(dp879
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p880
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p881
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p882
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p883
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p884
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p885
sa(dp886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p887
sg5
S'http://bio2rdf.org/drugbank:DB00562'
p888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p889
sg24
Nsg25
Nsg26
S'BENZTHIAZIDE'
p890
sg28
Nsg29
S'Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| \r'
p891
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aleve'
p892
sa(dp893
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p894
sg5
S'http://bio2rdf.org/drugbank:DB01210'
p895
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p896
sg24
Nsg25
Nsg26
S'Betagan'
p897
sg28
Nsg29
S'Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.| \r'
p898
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPINEPHRINE'
p899
sa(dp900
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01435'
p901
sg5
S'http://bio2rdf.org/drugbank:DB00068'
p902
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p903
sg24
Nsg25
Nsg26
S'Betaseron'
p904
sg28
Nsg29
S'Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| \r'
p905
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANTIPYRINE'
p906
sa(dp907
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p908
sg5
S'http://bio2rdf.org/drugbank:DB01294'
p909
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p910
sg24
Nsg25
Nsg26
S'BISMUTH SUBSALICYLATE'
p911
sg28
Nsg29
S'Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| \r'
p912
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ENOXACIN'
p913
sa(dp914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p915
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p917
sg24
Nsg25
Nsg26
S'Brevibloc'
p918
sg28
Nsg29
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p919
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p920
sa(dp921
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p922
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p923
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p924
sg24
Nsg25
Nsg26
S'Brevibloc'
p925
sg28
Nsg29
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p926
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPINEPHRINE'
p927
sa(dp928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p929
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p931
sg24
Nsg25
Nsg26
S'Brevibloc'
p932
sg28
Nsg29
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p933
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p934
sa(dp935
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p936
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p937
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p938
sg24
Nsg25
Nsg26
S'Brevibloc'
p939
sg28
Nsg29
S'Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| \r'
p940
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p941
sa(dp942
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p943
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p944
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p945
sg24
Nsg25
Nsg26
S'BUPRENORPHINE'
p946
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p947
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p948
sa(dp949
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p950
sg5
S'http://bio2rdf.org/drugbank:DB00490'
p951
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p952
sg24
Nsg25
Nsg26
S'BUSPIRONE'
p953
sg28
Nsg29
S'In vitro, buspirone may displace less firmly bound drugs like digoxin.| \r'
p954
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p955
sa(dp956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p957
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p959
sg24
Nsg25
Nsg26
S'BUTALBITAL'
p960
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p961
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p962
sa(dp963
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p964
sg5
S'http://bio2rdf.org/drugbank:DB00241'
p965
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p966
sg24
Nsg25
Nsg26
S'BUTALBITAL'
p967
sg28
Nsg29
S'Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| \r'
p968
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p969
sa(dp970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p971
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p973
sg24
Nsg25
Nsg26
S'BUTORPHANOL'
p974
sg28
Nsg29
S'Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| \r'
p975
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p976
sa(dp977
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p978
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p979
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p980
sg24
Nsg25
Nsg26
S'BUTORPHANOL'
p981
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p982
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p983
sa(dp984
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p985
sg5
S'http://bio2rdf.org/drugbank:DB00762'
p986
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p987
sg24
Nsg25
Nsg26
S'Camptosar'
p988
sg28
Nsg29
S'Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.| \r'
p989
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p990
sa(dp991
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p992
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p993
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p994
sg24
Nsg25
Nsg26
S'Cancidas'
p995
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p996
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p997
sa(dp998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p999
sg5
S'http://bio2rdf.org/drugbank:DB00520'
p1000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1001
sg24
Nsg25
Nsg26
S'Cancidas'
p1002
sg28
Nsg29
S'When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| \r'
p1003
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p1004
sa(dp1005
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p1006
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p1007
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1008
sg24
Nsg25
Nsg26
S'CARBACHOL'
p1009
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p1010
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p1011
sa(dp1012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p1013
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p1014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1015
sg24
Nsg25
Nsg26
S'Carboptic'
p1016
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p1017
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p1018
sa(dp1019
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1020
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1021
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1022
sg24
Nsg25
Nsg26
S'Celebrex'
p1023
sg28
Nsg29
S'Aspirin: CELEBREX can be used with low dose aspirin.| \r'
p1024
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p1025
sa(dp1026
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1027
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1028
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1029
sg24
Nsg25
Nsg26
S'Celebrex'
p1030
sg28
Nsg29
S'CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| \r'
p1031
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p1032
sa(dp1033
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1034
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1035
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1036
sg24
Nsg25
Nsg26
S'CELECOXIB'
p1037
sg28
Nsg29
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p1038
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p1039
sa(dp1040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1041
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p1042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1043
sg24
Nsg25
Nsg26
S'CELECOXIB'
p1044
sg28
Nsg29
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p1045
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p1046
sa(dp1047
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p1048
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p1049
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1050
sg24
Nsg25
Nsg26
S'CEPHALEXIN ANHYDROUS'
p1051
sg28
Nsg29
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p1052
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p1053
sa(dp1054
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p1055
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p1056
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1057
sg24
Nsg25
Nsg26
S'CEPHALEXIN ANHYDROUS'
p1058
sg28
Nsg29
S'Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| \r'
p1059
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p1060
sa(dp1061
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p1062
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p1063
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1064
sg24
Nsg25
Nsg26
S'CEPHALEXIN ANHYDROUS'
p1065
sg28
Nsg29
S'Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p1066
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p1067
sa(dp1068
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p1069
sg5
S'http://bio2rdf.org/drugbank:DB00053'
p1070
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1071
sg24
Nsg25
Nsg26
S'Cerezyme'
p1072
sg28
Nsg29
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p1073
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zavesca'
p1074
sa(dp1075
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1076
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1077
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1078
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p1079
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1080
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p1081
sa(dp1082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p1083
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1085
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p1086
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1087
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BROMOCRIPTINE'
p1088
sa(dp1089
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01219'
p1090
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1091
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1092
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p1093
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1094
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DANTROLENE'
p1095
sa(dp1096
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00052'
p1097
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1098
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1099
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p1100
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1101
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Somatropin'
p1102
sa(dp1103
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p1104
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p1105
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1106
sg24
Nsg25
Nsg26
S'CHLOROTRIANISENE'
p1107
sg28
Nsg29
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p1108
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tamoxifen'
p1109
sa(dp1110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1111
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p1112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1113
sg24
Nsg25
Nsg26
S'CHLORPROMAZINE'
p1114
sg28
Nsg29
S'The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| \r'
p1115
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMITRIPTYLINE'
p1116
sa(dp1117
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1118
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p1119
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1120
sg24
Nsg25
Nsg26
S'CHLORPROPAMIDE'
p1121
sg28
Nsg29
S'Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p1122
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p1123
sa(dp1124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p1125
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p1126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1127
sg24
Nsg25
Nsg26
S'CHLORPROPAMIDE'
p1128
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p1129
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p1130
sa(dp1131
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1132
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p1133
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1134
sg24
Nsg25
Nsg26
S'CINACALCET'
p1135
sg28
Nsg29
S'Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| \r'
p1136
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMITRIPTYLINE'
p1137
sa(dp1138
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p1139
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1140
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1141
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p1142
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1143
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p1144
sa(dp1145
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p1146
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1147
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1148
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p1149
sg28
Nsg29
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p1150
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p1151
sa(dp1152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1153
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1155
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p1156
sg28
Nsg29
S'In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| \r'
p1157
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p1158
sa(dp1159
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1160
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p1161
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1162
sg24
Nsg25
Nsg26
S'CIPROFLOXACIN'
p1163
sg28
Nsg29
S'Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.| \r'
p1164
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p1165
sa(dp1166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1167
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1169
sg24
Nsg25
Nsg26
S'Cisapride'
p1170
sg28
Nsg29
S'Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| \r'
p1171
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1172
sa(dp1173
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1174
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1175
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1176
sg24
Nsg25
Nsg26
S'Cisapride'
p1177
sg28
Nsg29
S'Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| \r'
p1178
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1179
sa(dp1180
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00489'
p1181
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1182
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1183
sg24
Nsg25
Nsg26
S'Cisapride'
p1184
sg28
Nsg29
S'Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| \r'
p1185
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sotalol'
p1186
sa(dp1187
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1188
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p1189
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1190
sg24
Nsg25
Nsg26
S'Cisapride'
p1191
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1192
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p1193
sa(dp1194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00782'
p1195
sg5
S'http://bio2rdf.org/drugbank:DB01068'
p1196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1197
sg24
Nsg25
Nsg26
S'CLONAZEPAM'
p1198
sg28
Nsg29
S'In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| \r'
p1199
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROPANTHELINE'
p1200
sa(dp1201
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1202
sg5
S'http://bio2rdf.org/drugbank:DB00575'
p1203
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1204
sg24
Nsg25
Nsg26
S'CLONIDINE'
p1205
sg28
Nsg29
S'Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| \r'
p1206
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1207
sa(dp1208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p1209
sg5
S'http://bio2rdf.org/drugbank:DB00257'
p1210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1211
sg24
Nsg25
Nsg26
S'CLOTRIMAZOLE'
p1212
sg28
Nsg29
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p1213
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIMETREXATE'
p1214
sa(dp1215
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1216
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1217
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1218
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1219
sg28
Nsg29
S'Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.| \r'
p1220
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1221
sa(dp1222
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p1223
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1224
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1225
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1226
sg28
Nsg29
S'Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| \r'
p1227
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atropine'
p1228
sa(dp1229
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01228'
p1230
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1231
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1232
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1233
sg28
Nsg29
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p1234
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Encainide'
p1235
sa(dp1236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1237
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1239
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1240
sg28
Nsg29
S'Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.| \r'
p1241
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p1242
sa(dp1243
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p1244
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1245
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1246
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1247
sg28
Nsg29
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1248
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p1249
sa(dp1250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p1251
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1253
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1254
sg28
Nsg29
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1255
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p1256
sa(dp1257
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p1258
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p1259
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1260
sg24
Nsg25
Nsg26
S'CLOZAPINE'
p1261
sg28
Nsg29
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p1262
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p1263
sa(dp1264
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1265
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p1266
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1267
sg24
Nsg25
Nsg26
S'Copegus'
p1268
sg28
Nsg29
S'Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| \r'
p1269
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p1270
sa(dp1271
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1272
sg5
S'http://bio2rdf.org/drugbank:DB01136'
p1273
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1274
sg24
Nsg25
Nsg26
S'Coreg'
p1275
sg28
Nsg29
S'As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| \r'
p1276
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p1277
sa(dp1278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p1279
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p1280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1281
sg24
Nsg25
Nsg26
S'Crixivan'
p1282
sg28
Nsg29
S'Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| \r'
p1283
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p1284
sa(dp1285
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00705'
p1286
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p1287
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1288
sg24
Nsg25
Nsg26
S'Crixivan'
p1289
sg28
Nsg29
S'Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| \r'
p1290
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DELAVIRDINE'
p1291
sa(dp1292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p1293
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1295
sg24
Nsg25
Nsg26
S'Cyclophosphamide'
p1296
sg28
Nsg29
S'Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| \r'
p1297
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALLOPURINOL'
p1298
sa(dp1299
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00694'
p1300
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1301
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1302
sg24
Nsg25
Nsg26
S'Cyclophosphamide'
p1303
sg28
Nsg29
S'Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.| \r'
p1304
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cerubidine'
p1305
sa(dp1306
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1307
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p1308
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1309
sg24
Nsg25
Nsg26
S'Cyclophosphamide'
p1310
sg28
Nsg29
S'The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| \r'
p1311
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p1312
sa(dp1313
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00773'
p1314
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p1315
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1316
sg24
Nsg25
Nsg26
S'Cyclosporin A'
p1317
sg28
Nsg29
S'High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| \r'
p1318
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Etoposide'
p1319
sa(dp1320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p1321
sg5
S'http://bio2rdf.org/drugbank:DB00357'
p1322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1323
sg24
Nsg25
Nsg26
S'Cytadren'
p1324
sg28
Nsg29
S'Cytadren accelerates the metabolism of dexamethasone;| \r'
p1325
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p1326
sa(dp1327
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p1328
sg5
S'http://bio2rdf.org/drugbank:DB00987'
p1329
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1330
sg24
Nsg25
Nsg26
S'Cytosine arabinoside'
p1331
sg28
Nsg29
S'Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| \r'
p1332
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCYTOSINE'
p1333
sa(dp1334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00344'
p1335
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p1336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1337
sg24
Nsg25
Nsg26
S'd-amphetamine'
p1338
sg28
Nsg29
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p1339
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROTRIPTYLINE'
p1340
sa(dp1341
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p1342
sg5
S'http://bio2rdf.org/drugbank:DB01219'
p1343
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1344
sg24
Nsg25
Nsg26
S'DANTROLENE'
p1345
sg28
Nsg29
S'Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| \r'
p1346
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VECURONIUM'
p1347
sa(dp1348
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p1349
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1350
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1351
sg24
Nsg25
Nsg26
S'DAPSONE'
p1352
sg28
Nsg29
S'If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.| \r'
p1353
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFAZIMINE'
p1354
sa(dp1355
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00845'
p1356
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1357
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1358
sg24
Nsg25
Nsg26
S'DAPSONE'
p1359
sg28
Nsg29
S'Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.| \r'
p1360
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lamprene'
p1361
sa(dp1362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00205'
p1363
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p1364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1365
sg24
Nsg25
Nsg26
S'DAPSONE'
p1366
sg28
Nsg29
S'With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| \r'
p1367
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PYRIMETHAMINE'
p1368
sa(dp1369
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p1370
sg5
S'http://bio2rdf.org/drugbank:DB01245'
p1371
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1372
sg24
Nsg25
Nsg26
S'DECAMETHONIUM'
p1373
sg28
Nsg29
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p1374
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coly-Mycin M'
p1375
sa(dp1376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1377
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p1378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1379
sg24
Nsg25
Nsg26
S'DELAVIRDINE'
p1380
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p1381
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p1382
sa(dp1383
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p1384
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p1385
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1386
sg24
Nsg25
Nsg26
S'DELAVIRDINE'
p1387
sg28
Nsg29
S'To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| \r'
p1388
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p1389
sa(dp1390
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1391
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p1392
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1393
sg24
Nsg25
Nsg26
S'Demser'
p1394
sg28
Nsg29
S'Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.| \r'
p1395
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1396
sa(dp1397
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p1398
sg5
S'http://bio2rdf.org/drugbank:DB00765'
p1399
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1400
sg24
Nsg25
Nsg26
S'Demser'
p1401
sg28
Nsg29
S'Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. | \r'
p1402
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p1403
sa(dp1404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00518'
p1405
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1407
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p1408
sg28
Nsg29
S'Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| \r'
p1409
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALBENDAZOLE'
p1410
sa(dp1411
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1412
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1413
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1414
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p1415
sg28
Nsg29
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p1416
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p1417
sa(dp1418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1419
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1421
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p1422
sg28
Nsg29
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| \r'
p1423
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p1424
sa(dp1425
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p1426
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p1427
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1428
sg24
Nsg25
Nsg26
S'DEXAMETHASONE'
p1429
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p1430
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p1431
sa(dp1432
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1433
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p1434
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1435
sg24
Nsg25
Nsg26
S'DEXBROMPHENIRAMINE'
p1436
sg28
Nsg29
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p1437
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1438
sa(dp1439
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1440
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p1441
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1442
sg24
Nsg25
Nsg26
S'DEXBROMPHENIRAMINE'
p1443
sg28
Nsg29
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p1444
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1445
sa(dp1446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01364'
p1447
sg5
S'http://bio2rdf.org/drugbank:DB00633'
p1448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1449
sg24
Nsg25
Nsg26
S'DEXMEDETOMIDINE'
p1450
sg28
Nsg29
S'In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. | At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. | We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.| \r'
p1451
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EPHEDRINE'
p1452
sa(dp1453
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1454
sg5
S'http://bio2rdf.org/drugbank:DB00514'
p1455
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1456
sg24
Nsg25
Nsg26
S'Dextromethorphan'
p1457
sg28
Nsg29
S'Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| \r'
p1458
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p1459
sa(dp1460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1461
sg5
S'http://bio2rdf.org/drugbank:DB01209'
p1462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1463
sg24
Nsg25
Nsg26
S'DEZOCINE'
p1464
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1465
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p1466
sa(dp1467
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p1468
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p1469
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1470
sg24
Nsg25
Nsg26
S'Diamox'
p1471
sg28
Nsg29
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p1472
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p1473
sa(dp1474
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p1475
sg5
S'http://bio2rdf.org/drugbank:DB00819'
p1476
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1477
sg24
Nsg25
Nsg26
S'Diamox'
p1478
sg28
Nsg29
S'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| \r'
p1479
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p1480
sa(dp1481
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1482
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p1483
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1484
sg24
Nsg25
Nsg26
S'DIAZEPAM'
p1485
sg28
Nsg29
S'Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| \r'
p1486
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p1487
sa(dp1488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p1489
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p1490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1491
sg24
Nsg25
Nsg26
S'DIAZEPAM'
p1492
sg28
Nsg29
S'Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| \r'
p1493
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALDECOXIB'
p1494
sa(dp1495
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p1496
sg5
S'http://bio2rdf.org/drugbank:DB01119'
p1497
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1498
sg24
Nsg25
Nsg26
S'DIAZOXIDE'
p1499
sg28
Nsg29
S'Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| \r'
p1500
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HYDRALAZINE'
p1501
sa(dp1502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1503
sg5
S'http://bio2rdf.org/drugbank:DB00804'
p1504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1505
sg24
Nsg25
Nsg26
S'DICYCLOMINE'
p1506
sg28
Nsg29
S'Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| \r'
p1507
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p1508
sa(dp1509
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p1510
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1511
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1512
sg24
Nsg25
Nsg26
S'DIDANOSINE'
p1513
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p1514
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p1515
sa(dp1516
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p1517
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1518
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1519
sg24
Nsg25
Nsg26
S'DIDANOSINE'
p1520
sg28
Nsg29
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p1521
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p1522
sa(dp1523
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p1524
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1525
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1526
sg24
Nsg25
Nsg26
S'Diflucan'
p1527
sg28
Nsg29
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p1528
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLIPIZIDE'
p1529
sa(dp1530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1531
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1533
sg24
Nsg25
Nsg26
S'Diflucan'
p1534
sg28
Nsg29
S'Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. | \r'
p1535
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p1536
sa(dp1537
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p1538
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1539
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1540
sg24
Nsg25
Nsg26
S'Diflucan'
p1541
sg28
Nsg29
S'DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | \r'
p1542
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p1543
sa(dp1544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1545
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1547
sg24
Nsg25
Nsg26
S'Diflunisal'
p1548
sg28
Nsg29
S'Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| \r'
p1549
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p1550
sa(dp1551
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p1552
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1553
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1554
sg24
Nsg25
Nsg26
S'Diflunisal'
p1555
sg28
Nsg29
S'Therefore, diflunisal and INDOCIN should not be used concomitantly.| \r'
p1556
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Indocin'
p1557
sa(dp1558
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p1559
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p1560
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1561
sg24
Nsg25
Nsg26
S'Diflunisal'
p1562
sg28
Nsg29
S'Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| \r'
p1563
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NAPROXEN'
p1564
sa(dp1565
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p1566
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1567
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1568
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1569
sg28
Nsg29
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p1570
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Adenocard'
p1571
sa(dp1572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p1573
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1575
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1576
sg28
Nsg29
S'In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.| \r'
p1577
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMINOSALICYLIC ACID'
p1578
sa(dp1579
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p1580
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1581
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1582
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1583
sg28
Nsg29
S'These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.| \r'
p1584
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p1585
sa(dp1586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p1587
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1589
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1590
sg28
Nsg29
S'When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| \r'
p1591
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Brevibloc'
p1592
sa(dp1593
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p1594
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1595
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1596
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1597
sg28
Nsg29
S'Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| \r'
p1598
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CONIVAPTAN'
p1599
sa(dp1600
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p1601
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1602
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1603
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1604
sg28
Nsg29
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p1605
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coreg'
p1606
sa(dp1607
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01136'
p1608
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1609
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1610
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1611
sg28
Nsg29
S'Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| \r'
p1612
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coreg'
p1613
sa(dp1614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1615
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1617
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1618
sg28
Nsg29
S'Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.| \r'
p1619
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1620
sa(dp1621
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1622
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1623
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1624
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1625
sg28
Nsg29
S'In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p1626
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p1627
sa(dp1628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p1629
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1631
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1632
sg28
Nsg29
S'However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p1633
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Flolan'
p1634
sa(dp1635
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1636
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1637
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1638
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1639
sg28
Nsg29
S'It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| \r'
p1640
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1641
sa(dp1642
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p1643
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1644
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1645
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1646
sg28
Nsg29
S'Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | \r'
p1647
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p1648
sa(dp1649
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01261'
p1650
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1651
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1652
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1653
sg28
Nsg29
S'Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | \r'
p1654
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SITAGLIPTIN'
p1655
sa(dp1656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00795'
p1657
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1659
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1660
sg28
Nsg29
S'Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | \r'
p1661
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SULFASALAZINE'
p1662
sa(dp1663
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p1664
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p1665
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1666
sg24
Nsg25
Nsg26
S'DIGOXIN'
p1667
sg28
Nsg29
S'Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.| \r'
p1668
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vaprisol'
p1669
sa(dp1670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p1671
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1673
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p1674
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p1675
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Axert'
p1676
sa(dp1677
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p1678
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1679
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1680
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p1681
sg28
Nsg29
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p1682
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Frova'
p1683
sa(dp1684
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p1685
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1686
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1687
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p1688
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p1689
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NARATRIPTAN'
p1690
sa(dp1691
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p1692
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1693
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1694
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p1695
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p1696
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p1697
sa(dp1698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1699
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1701
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p1702
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1703
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p1704
sa(dp1705
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p1706
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p1707
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1708
sg24
Nsg25
Nsg26
S'DIHYDROERGOTAMINE'
p1709
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p1710
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p1711
sa(dp1712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p1713
sg5
S'http://bio2rdf.org/drugbank:DB01231'
p1714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1715
sg24
Nsg25
Nsg26
S'DIPHENIDOL'
p1716
sg28
Nsg29
S'apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.| \r'
p1717
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APOMORPHINE'
p1718
sa(dp1719
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1720
sg5
S'http://bio2rdf.org/drugbank:DB01081'
p1721
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1722
sg24
Nsg25
Nsg26
S'DIPHENOXYLATE'
p1723
sg28
Nsg29
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p1724
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1725
sa(dp1726
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00813'
p1727
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p1728
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1729
sg24
Nsg25
Nsg26
S'Diprivan'
p1730
sg28
Nsg29
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p1731
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fentanyl'
p1732
sa(dp1733
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p1734
sg5
S'http://bio2rdf.org/drugbank:DB00818'
p1735
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1736
sg24
Nsg25
Nsg26
S'Diprivan'
p1737
sg28
Nsg29
S'The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | \r'
p1738
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MEPERIDINE'
p1739
sa(dp1740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1741
sg5
S'http://bio2rdf.org/drugbank:DB04817'
p1742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1743
sg24
Nsg25
Nsg26
S'Dipyrone'
p1744
sg28
Nsg29
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p1745
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p1746
sa(dp1747
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01390'
p1748
sg5
S'http://bio2rdf.org/drugbank:DB00841'
p1749
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1750
sg24
Nsg25
Nsg26
S'Dobutamine'
p1751
sg28
Nsg29
S'norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | \r'
p1752
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SODIUM BICARBONATE'
p1753
sa(dp1754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1755
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p1756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1757
sg24
Nsg25
Nsg26
S'Dolasetron'
p1758
sg28
Nsg29
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p1759
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p1760
sa(dp1761
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p1762
sg5
S'http://bio2rdf.org/drugbank:DB00248'
p1763
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1764
sg24
Nsg25
Nsg26
S'Dostinex'
p1765
sg28
Nsg29
S'DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.| \r'
p1766
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p1767
sa(dp1768
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p1769
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1770
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1771
sg24
Nsg25
Nsg26
S'DULOXETINE'
p1772
sg28
Nsg29
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1773
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMITRIPTYLINE'
p1774
sa(dp1775
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1776
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1777
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1778
sg24
Nsg25
Nsg26
S'DULOXETINE'
p1779
sg28
Nsg29
S'Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| \r'
p1780
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p1781
sa(dp1782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p1783
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1785
sg24
Nsg25
Nsg26
S'DULOXETINE'
p1786
sg28
Nsg29
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1787
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IMIPRAMINE'
p1788
sa(dp1789
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00540'
p1790
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p1791
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1792
sg24
Nsg25
Nsg26
S'DULOXETINE'
p1793
sg28
Nsg29
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p1794
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORTRIPTYLINE'
p1795
sa(dp1796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1797
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1799
sg24
Nsg25
Nsg26
S'Duragesic'
p1800
sg28
Nsg29
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p1801
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1802
sa(dp1803
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p1804
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p1805
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1806
sg24
Nsg25
Nsg26
S'EFAVIRENZ'
p1807
sg28
Nsg29
S'In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| \r'
p1808
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p1809
sa(dp1810
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1811
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1812
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1813
sg24
Nsg25
Nsg26
S'Enablex'
p1814
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1815
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1816
sa(dp1817
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p1818
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1819
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1820
sg24
Nsg25
Nsg26
S'Enablex'
p1821
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1822
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p1823
sa(dp1824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1825
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p1826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1827
sg24
Nsg25
Nsg26
S'Enablex'
p1828
sg28
Nsg29
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p1829
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p1830
sa(dp1831
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p1832
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1833
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1834
sg24
Nsg25
Nsg26
S'ENOXACIN'
p1835
sg28
Nsg29
S'Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| \r'
p1836
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BISMUTH SUBSALICYLATE'
p1837
sa(dp1838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1839
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1841
sg24
Nsg25
Nsg26
S'ENOXACIN'
p1842
sg28
Nsg29
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p1843
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1844
sa(dp1845
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1846
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p1847
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1848
sg24
Nsg25
Nsg26
S'ENOXACIN'
p1849
sg28
Nsg29
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| \r'
p1850
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p1851
sa(dp1852
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p1853
sg5
S'http://bio2rdf.org/drugbank:DB04880'
p1854
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1855
sg24
Nsg25
Nsg26
S'ENOXIMONE'
p1856
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p1857
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p1858
sa(dp1859
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1860
sg5
S'http://bio2rdf.org/drugbank:DB00159'
p1861
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p1862
sg24
Nsg25
Nsg26
S'EPA'
p1863
sg28
Nsg29
S'Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).| \r'
p1864
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p1865
sa(dp1866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00633'
p1867
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p1868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1869
sg24
Nsg25
Nsg26
S'EPHEDRINE'
p1870
sg28
Nsg29
S'Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#x0D;|\r'
p1871
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXMEDETOMIDINE'
p1872
sa(dp1873
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01403'
p1874
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p1875
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1876
sg24
Nsg25
Nsg26
S'EPHEDRINE'
p1877
sg28
Nsg29
S'Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | \r'
p1878
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVOMEPROMAZINE'
p1879
sa(dp1880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p1881
sg5
S'http://bio2rdf.org/drugbank:DB01364'
p1882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1883
sg24
Nsg25
Nsg26
S'EPHEDRINE'
p1884
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p1885
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p1886
sa(dp1887
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p1888
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p1889
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1890
sg24
Nsg25
Nsg26
S'EPINEPHRINE'
p1891
sg28
Nsg29
S'Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| \r'
p1892
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p1893
sa(dp1894
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01064'
p1895
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p1896
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1897
sg24
Nsg25
Nsg26
S'EPINEPHRINE'
p1898
sg28
Nsg29
S'Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| \r'
p1899
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Isoproterenol'
p1900
sa(dp1901
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1902
sg5
S'http://bio2rdf.org/drugbank:DB00848'
p1903
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1904
sg24
Nsg25
Nsg26
S'Ergamisol'
p1905
sg28
Nsg29
S'ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.| \r'
p1906
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p1907
sa(dp1908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p1909
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1911
sg24
Nsg25
Nsg26
S'Ergomar'
p1912
sg28
Nsg29
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p1913
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Triacetyloleandomycin'
p1914
sa(dp1915
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p1916
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1917
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1918
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p1919
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| \r'
p1920
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Axert'
p1921
sa(dp1922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p1923
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1925
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p1926
sg28
Nsg29
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p1927
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Frova'
p1928
sa(dp1929
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p1930
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1931
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1932
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p1933
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p1934
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NARATRIPTAN'
p1935
sa(dp1936
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p1937
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1938
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1939
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p1940
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p1941
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p1942
sa(dp1943
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p1944
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p1945
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1946
sg24
Nsg25
Nsg26
S'ERGOTAMINE'
p1947
sg28
Nsg29
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | \r'
p1948
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p1949
sa(dp1950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p1951
sg5
S'http://bio2rdf.org/drugbank:DB00303'
p1952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1953
sg24
Nsg25
Nsg26
S'ERTAPENEM'
p1954
sg28
Nsg29
S'Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.| \r'
p1955
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p1956
sa(dp1957
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00215'
p1958
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p1959
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1960
sg24
Nsg25
Nsg26
S'ESCITALOPRAM'
p1961
sg28
Nsg29
S'Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| \r'
p1962
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Celexa'
p1963
sa(dp1964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p1965
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1967
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p1968
sg28
Nsg29
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p1969
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESTAZOLAM'
p1970
sa(dp1971
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1972
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1973
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p1974
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p1975
sg28
Nsg29
S'Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| \r'
p1976
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1977
sa(dp1978
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p1979
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p1980
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1981
sg24
Nsg25
Nsg26
S'ESTAZOLAM'
p1982
sg28
Nsg29
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p1983
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p1984
sa(dp1985
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00368'
p1986
sg5
S'http://bio2rdf.org/drugbank:DB00783'
p1987
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p1988
sg24
Nsg25
Nsg26
S'Estradiol'
p1989
sg28
Nsg29
S'Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). | Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). | \r'
p1990
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Noradrenaline'
p1991
sa(dp1992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1993
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p1994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p1995
sg24
Nsg25
Nsg26
S'ESZOPICLONE'
p1996
sg28
Nsg29
S'The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| \r'
p1997
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p1998
sa(dp1999
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00334'
p2000
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p2001
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2002
sg24
Nsg25
Nsg26
S'ESZOPICLONE'
p2003
sg28
Nsg29
S'Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.| \r'
p2004
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'OLANZAPINE'
p2005
sa(dp2006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p2007
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p2008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2009
sg24
Nsg25
Nsg26
S'ETHAMBUTOL'
p2010
sg28
Nsg29
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p2011
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM HYDROXIDE'
p2012
sa(dp2013
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB06723'
p2014
sg5
S'http://bio2rdf.org/drugbank:DB00330'
p2015
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2016
sg24
Nsg25
Nsg26
S'ETHAMBUTOL'
p2017
sg28
Nsg29
S'The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| \r'
p2018
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM HYDROXIDE'
p2019
sa(dp2020
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00260'
p2021
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p2022
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2023
sg24
Nsg25
Nsg26
S'ETHIONAMIDE'
p2024
sg28
Nsg29
S'In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| \r'
p2025
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CYCLOSERINE'
p2026
sa(dp2027
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p2028
sg5
S'http://bio2rdf.org/drugbank:DB00311'
p2029
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2030
sg24
Nsg25
Nsg26
S'ETHOXZOLAMIDE'
p2031
sg28
Nsg29
S'Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.| \r'
p2032
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p2033
sa(dp2034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p2035
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p2036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2037
sg24
Nsg25
Nsg26
S'Etodolac'
p2038
sg28
Nsg29
S'Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| \r'
p2039
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p2040
sa(dp2041
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p2042
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2043
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2044
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2045
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2046
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Agenerase'
p2047
sa(dp2048
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p2049
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2050
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2051
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2052
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2053
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p2054
sa(dp2055
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2056
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2057
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2058
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2059
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2060
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atromid-S'
p2061
sa(dp2062
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2063
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2064
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2065
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2066
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2067
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFIBRATE'
p2068
sa(dp2069
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p2070
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2071
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2072
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2073
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2074
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Crixivan'
p2075
sa(dp2076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p2077
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2079
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2080
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2081
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dilantin'
p2082
sa(dp2083
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p2084
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2085
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2086
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2087
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2088
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Felbatol'
p2089
sa(dp2090
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2091
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2092
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2093
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2094
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2095
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fortovase'
p2096
sa(dp2097
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00400'
p2098
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2099
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2100
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2101
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2102
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Gris-PEG'
p2103
sa(dp2104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p2105
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2107
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2108
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2109
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Invirase'
p2110
sa(dp2111
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2112
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2113
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2114
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2115
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2116
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Kadian'
p2117
sa(dp2118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p2119
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2121
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2122
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2123
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lipitor'
p2124
sa(dp2125
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p2126
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2127
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2128
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2129
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2130
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MS Contin'
p2131
sa(dp2132
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2133
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2134
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2135
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2136
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2137
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Neoral '
p2138
sa(dp2139
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2140
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2141
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2142
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2143
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2144
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nizoral'
p2145
sa(dp2146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2147
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2149
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2150
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2151
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Norvir'
p2152
sa(dp2153
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2154
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2155
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2156
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2157
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2158
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p2159
sa(dp2160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p2161
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2163
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2164
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2165
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p2166
sa(dp2167
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p2168
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2169
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2170
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2171
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2172
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Prelone'
p2173
sa(dp2174
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2175
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2176
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2177
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2178
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2179
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifadin'
p2180
sa(dp2181
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2182
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2183
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2184
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2185
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2186
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p2187
sa(dp2188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p2189
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2191
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2192
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2193
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sandimmune '
p2194
sa(dp2195
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p2196
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2197
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2198
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2199
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2200
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sporanox'
p2201
sa(dp2202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p2203
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2205
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2206
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2207
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TEGretol'
p2208
sa(dp2209
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p2210
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2211
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2212
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2213
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2214
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Theo-Dur'
p2215
sa(dp2216
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00273'
p2217
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2218
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2219
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2220
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2221
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Topamax'
p2222
sa(dp2223
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p2224
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2225
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2226
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2227
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2228
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Trileptal'
p2229
sa(dp2230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p2231
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2233
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2234
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2235
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tylenol'
p2236
sa(dp2237
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p2238
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p2239
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2240
sg24
Nsg25
Nsg26
S'ETONOGESTREL'
p2241
sg28
Nsg29
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p2242
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p2243
sa(dp2244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p2245
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2247
sg24
Nsg25
Nsg26
S'Evista'
p2248
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2249
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFIBRATE'
p2250
sa(dp2251
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2252
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2253
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2254
sg24
Nsg25
Nsg26
S'Evista'
p2255
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2256
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p2257
sa(dp2258
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01119'
p2259
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2260
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2261
sg24
Nsg25
Nsg26
S'Evista'
p2262
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2263
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZOXIDE'
p2264
sa(dp2265
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p2266
sg5
S'http://bio2rdf.org/drugbank:DB00481'
p2267
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2268
sg24
Nsg25
Nsg26
S'Evista'
p2269
sg28
Nsg29
S'Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | \r'
p2270
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NAPROXEN'
p2271
sa(dp2272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p2273
sg5
S'http://bio2rdf.org/drugbank:DB01609'
p2274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2275
sg24
Nsg25
Nsg26
S'Exjade'
p2276
sg28
Nsg29
S'Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.| \r'
p2277
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p2278
sa(dp2279
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2280
sg5
S'http://bio2rdf.org/drugbank:DB01155'
p2281
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2282
sg24
Nsg25
Nsg26
S'Factive'
p2283
sg28
Nsg29
S'Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.| \r'
p2284
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p2285
sa(dp2286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p2287
sg5
S'http://bio2rdf.org/drugbank:DB00927'
p2288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2289
sg24
Nsg25
Nsg26
S'FAMOTIDINE'
p2290
sg28
Nsg29
S'H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.| \r'
p2291
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cefditoren Pivoxil'
p2292
sa(dp2293
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p2294
sg5
S'http://bio2rdf.org/drugbank:DB00949'
p2295
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2296
sg24
Nsg25
Nsg26
S'Felbatol'
p2297
sg28
Nsg29
S'Valproate: Felbatol  causes an increase in steady-state valproate concentrations.| \r'
p2298
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p2299
sa(dp2300
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2301
sg5
S'http://bio2rdf.org/drugbank:DB00554'
p2302
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2303
sg24
Nsg25
Nsg26
S'Feldene'
p2304
sg28
Nsg29
S'Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | \r'
p2305
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p2306
sa(dp2307
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2308
sg5
S'http://bio2rdf.org/drugbank:DB01023'
p2309
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2310
sg24
Nsg25
Nsg26
S'Felodipine'
p2311
sg28
Nsg29
S'Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| \r'
p2312
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p2313
sa(dp2314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p2315
sg5
S'http://bio2rdf.org/drugbank:DB01006'
p2316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2317
sg24
Nsg25
Nsg26
S'Femara'
p2318
sg28
Nsg29
S'(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.| \r'
p2319
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tamoxifen'
p2320
sa(dp2321
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00973'
p2322
sg5
S'http://bio2rdf.org/drugbank:DB01039'
p2323
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2324
sg24
Nsg25
Nsg26
S'FENOFIBRATE'
p2325
sg28
Nsg29
S'Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | \r'
p2326
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EZETIMIBE'
p2327
sa(dp2328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2329
sg5
S'http://bio2rdf.org/drugbank:DB00573'
p2330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2331
sg24
Nsg25
Nsg26
S'Fenoprofen'
p2332
sg28
Nsg29
S'Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.| \r'
p2333
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p2334
sa(dp2335
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2336
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2337
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2338
sg24
Nsg25
Nsg26
S'Fentanyl'
p2339
sg28
Nsg29
S'Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p2340
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p2341
sa(dp2342
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2343
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2344
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2345
sg24
Nsg25
Nsg26
S'Fentanyl'
p2346
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2347
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2348
sa(dp2349
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p2350
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2351
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2352
sg24
Nsg25
Nsg26
S'Fentanyl'
p2353
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2354
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p2355
sa(dp2356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2357
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2359
sg24
Nsg25
Nsg26
S'Fentanyl'
p2360
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2361
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p2362
sa(dp2363
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p2364
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2365
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2366
sg24
Nsg25
Nsg26
S'Fentanyl'
p2367
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p2368
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p2369
sa(dp2370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p2371
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p2372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2373
sg24
Nsg25
Nsg26
S'Fentanyl'
p2374
sg28
Nsg29
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p2375
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p2376
sa(dp2377
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2378
sg5
S'http://bio2rdf.org/drugbank:DB00924'
p2379
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2380
sg24
Nsg25
Nsg26
S'Flexeril'
p2381
sg28
Nsg29
S'FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| \r'
p2382
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p2383
sa(dp2384
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2385
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2386
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2387
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2388
sg28
Nsg29
S'Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. | \r'
p2389
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p2390
sa(dp2391
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p2392
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2393
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2394
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2395
sg28
Nsg29
S'Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| \r'
p2396
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CELECOXIB'
p2397
sa(dp2398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2399
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2401
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2402
sg28
Nsg29
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p2403
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2404
sa(dp2405
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2406
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2407
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2408
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2409
sg28
Nsg29
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p2410
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2411
sa(dp2412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2413
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2415
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2416
sg28
Nsg29
S'The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| \r'
p2417
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2418
sa(dp2419
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01067'
p2420
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2421
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2422
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2423
sg28
Nsg29
S'The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.| \r'
p2424
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GLIPIZIDE'
p2425
sa(dp2426
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00367'
p2427
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2428
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2429
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2430
sg28
Nsg29
S'While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | \r'
p2431
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LEVONORGESTREL'
p2432
sa(dp2433
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p2434
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2435
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2436
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2437
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p2438
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p2439
sa(dp2440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p2441
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p2442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2443
sg24
Nsg25
Nsg26
S'FLUCONAZOLE'
p2444
sg28
Nsg29
S'Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. | \r'
p2445
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p2446
sa(dp2447
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00552'
p2448
sg5
S'http://bio2rdf.org/drugbank:DB01073'
p2449
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2450
sg24
Nsg25
Nsg26
S'Fludara'
p2451
sg28
Nsg29
S'The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| \r'
p2452
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTOSTATIN'
p2453
sa(dp2454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p2455
sg5
S'http://bio2rdf.org/drugbank:DB01159'
p2456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2457
sg24
Nsg25
Nsg26
S'Fluothane'
p2458
sg28
Nsg29
S'FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| \r'
p2459
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TUBOCURARINE'
p2460
sa(dp2461
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p2462
sg5
S'http://bio2rdf.org/drugbank:DB00623'
p2463
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2464
sg24
Nsg25
Nsg26
S'FLUPHENAZINE'
p2465
sg28
Nsg29
S'There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.| \r'
p2466
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONIDINE'
p2467
sa(dp2468
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p2469
sg5
S'http://bio2rdf.org/drugbank:DB00712'
p2470
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2471
sg24
Nsg25
Nsg26
S'Flurbiprofen'
p2472
sg28
Nsg29
S'Concurrent use of flurbiprofen and aspirin is therefore not recommended.| \r'
p2473
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p2474
sa(dp2475
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p2476
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2477
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2478
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2479
sg28
Nsg29
S'Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.| \r'
p2480
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALOSETRON'
p2481
sa(dp2482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2483
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2485
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2486
sg28
Nsg29
S'Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| \r'
p2487
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p2488
sa(dp2489
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p2490
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2491
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2492
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2493
sg28
Nsg29
S'It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.| \r'
p2494
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p2495
sa(dp2496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2497
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2499
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2500
sg28
Nsg29
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2501
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p2502
sa(dp2503
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2504
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2505
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2506
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2507
sg28
Nsg29
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2508
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2509
sa(dp2510
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2511
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2512
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2513
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2514
sg28
Nsg29
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p2515
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p2516
sa(dp2517
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p2518
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2519
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2520
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2521
sg28
Nsg29
S'Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| \r'
p2522
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p2523
sa(dp2524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p2525
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2527
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2528
sg28
Nsg29
S'Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. | \r'
p2529
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ropivacaine'
p2530
sa(dp2531
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p2532
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2533
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2534
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2535
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p2536
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p2537
sa(dp2538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00857'
p2539
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2541
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2542
sg28
Nsg29
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p2543
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TERBINAFINE'
p2544
sa(dp2545
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p2546
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2547
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2548
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2549
sg28
Nsg29
S'Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.| RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. | \r'
p2550
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p2551
sa(dp2552
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2553
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p2554
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2555
sg24
Nsg25
Nsg26
S'FLUVOXAMINE'
p2556
sg28
Nsg29
S'Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| \r'
p2557
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Xanax'
p2558
sa(dp2559
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2560
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2561
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2562
sg24
Nsg25
Nsg26
S'FOSCARNET'
p2563
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p2564
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p2565
sa(dp2566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p2567
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2569
sg24
Nsg25
Nsg26
S'FOSCARNET'
p2570
sg28
Nsg29
S'Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| \r'
p2571
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p2572
sa(dp2573
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p2574
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2575
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2576
sg24
Nsg25
Nsg26
S'Foscavir'
p2577
sg28
Nsg29
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| \r'
p2578
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p2579
sa(dp2580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2581
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2583
sg24
Nsg25
Nsg26
S'Foscavir'
p2584
sg28
Nsg29
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| \r'
p2585
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p2586
sa(dp2587
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2588
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2589
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2590
sg24
Nsg25
Nsg26
S'Foscavir'
p2591
sg28
Nsg29
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| \r'
p2592
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p2593
sa(dp2594
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p2595
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p2596
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2597
sg24
Nsg25
Nsg26
S'Foscavir'
p2598
sg28
Nsg29
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| \r'
p2599
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p2600
sa(dp2601
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2602
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p2603
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2604
sg24
Nsg25
Nsg26
S'GEMFIBROZIL'
p2605
sg28
Nsg29
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p2606
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p2607
sa(dp2608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2609
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p2610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2611
sg24
Nsg25
Nsg26
S'GEMFIBROZIL'
p2612
sg28
Nsg29
S'Concomitant administration of gemfibrozil with Targretin capsules is not recommended.| \r'
p2613
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Targretin'
p2614
sa(dp2615
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2616
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2617
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2618
sg24
Nsg25
Nsg26
S'Gleevec'
p2619
sg28
Nsg29
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p2620
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2621
sa(dp2622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2623
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2625
sg24
Nsg25
Nsg26
S'Gleevec'
p2626
sg28
Nsg29
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p2627
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2628
sa(dp2629
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01100'
p2630
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p2631
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2632
sg24
Nsg25
Nsg26
S'Gleevec'
p2633
sg28
Nsg29
S'Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| \r'
p2634
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PIMOZIDE'
p2635
sa(dp2636
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p2637
sg5
S'http://bio2rdf.org/drugbank:DB01067'
p2638
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2639
sg24
Nsg25
Nsg26
S'GLIPIZIDE'
p2640
sg28
Nsg29
S'The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| \r'
p2641
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p2642
sa(dp2643
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00855'
p2644
sg5
S'http://bio2rdf.org/drugbank:DB00400'
p2645
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2646
sg24
Nsg25
Nsg26
S'GRISEOFULVIN'
p2647
sg28
Nsg29
S'It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.| \r'
p2648
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levulan Kerastick'
p2649
sa(dp2650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00350'
p2651
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p2652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2653
sg24
Nsg25
Nsg26
S'GUANETHIDINE'
p2654
sg28
Nsg29
S'If at all possible guanethidine should be discontinued well before minoxidil is begun. | \r'
p2655
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MINOXIDIL'
p2656
sa(dp2657
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p2658
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p2659
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2660
sg24
Nsg25
Nsg26
S'GUANETHIDINE'
p2661
sg28
Nsg29
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p2662
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zebeta'
p2663
sa(dp2664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p2665
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p2666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2667
sg24
Nsg25
Nsg26
S'GUANFACINE'
p2668
sg28
Nsg29
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p2669
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p2670
sa(dp2671
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2672
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2673
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2674
sg24
Nsg25
Nsg26
S'Haldol'
p2675
sg28
Nsg29
S'As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.| \r'
p2676
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p2677
sa(dp2678
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB03575'
p2679
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2680
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2681
sg24
Nsg25
Nsg26
S'HALOPERIDOL'
p2682
sg28
Nsg29
S'Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. | \r'
p2683
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PCP'
p2684
sa(dp2685
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p2686
sg5
S'http://bio2rdf.org/drugbank:DB00502'
p2687
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2688
sg24
Nsg25
Nsg26
S'HALOPERIDOL'
p2689
sg28
Nsg29
S'In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.| \r'
p2690
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p2691
sa(dp2692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2693
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p2694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2695
sg24
Nsg25
Nsg26
S'HCTZ'
p2696
sg28
Nsg29
S'In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.| \r'
p2697
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p2698
sa(dp2699
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2700
sg5
S'http://bio2rdf.org/drugbank:DB00072'
p2701
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2702
sg24
Nsg25
Nsg26
S'Herceptin'
p2703
sg28
Nsg29
S'Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | \r'
p2704
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB'
p2705
sa(dp2706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p2707
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p2708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2709
sg24
Nsg25
Nsg26
S'HIVID'
p2710
sg28
Nsg29
S'Concomitant use of HIVID with didanosine is not recommended.| \r'
p2711
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p2712
sa(dp2713
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00419'
p2714
sg5
S'http://bio2rdf.org/drugbank:DB06720'
p2715
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2716
sg24
Nsg25
Nsg26
S'Imiglucerase'
p2717
sg28
Nsg29
S'Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| \r'
p2718
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zavesca'
p2719
sa(dp2720
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p2721
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p2722
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2723
sg24
Nsg25
Nsg26
S'IMIPRAMINE'
p2724
sg28
Nsg29
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p2725
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p2726
sa(dp2727
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p2728
sg5
S'http://bio2rdf.org/drugbank:DB01427'
p2729
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2730
sg24
Nsg25
Nsg26
S'INAMRINONE'
p2731
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p2732
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p2733
sa(dp2734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p2735
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2737
sg24
Nsg25
Nsg26
S'Indocin'
p2738
sg28
Nsg29
S'In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.| \r'
p2739
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Diflunisal'
p2740
sa(dp2741
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2742
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2743
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2744
sg24
Nsg25
Nsg26
S'Indocin'
p2745
sg28
Nsg29
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p2746
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p2747
sa(dp2748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p2749
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2751
sg24
Nsg25
Nsg26
S'Indocin'
p2752
sg28
Nsg29
S'Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| \r'
p2753
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p2754
sa(dp2755
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2756
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2757
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2758
sg24
Nsg25
Nsg26
S'Indocin'
p2759
sg28
Nsg29
S'When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.| \r'
p2760
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p2761
sa(dp2762
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p2763
sg5
S'http://bio2rdf.org/drugbank:DB00328'
p2764
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2765
sg24
Nsg25
Nsg26
S'Indocin'
p2766
sg28
Nsg29
S'INDOCIN and triamterene should not be administered together.| \r'
p2767
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAMTERENE'
p2768
sa(dp2769
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2770
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2771
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2772
sg24
Nsg25
Nsg26
S'INH'
p2773
sg28
Nsg29
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p2774
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2775
sa(dp2776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00584'
p2777
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p2778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2779
sg24
Nsg25
Nsg26
S'INSPRA'
p2780
sg28
Nsg29
S'In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.| \r'
p2781
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Enalapril'
p2782
sa(dp2783
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2784
sg5
S'http://bio2rdf.org/drugbank:DB00700'
p2785
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2786
sg24
Nsg25
Nsg26
S'INSPRA'
p2787
sg28
Nsg29
S'A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.| \r'
p2788
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2789
sa(dp2790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2791
sg5
S'http://bio2rdf.org/drugbank:DB01267'
p2792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2793
sg24
Nsg25
Nsg26
S'Invega'
p2794
sg28
Nsg29
S'Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. | \r'
p2795
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p2796
sa(dp2797
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p2798
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p2799
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2800
sg24
Nsg25
Nsg26
S'Invirase'
p2801
sg28
Nsg29
S'Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| \r'
p2802
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p2803
sa(dp2804
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p2805
sg5
S'http://bio2rdf.org/drugbank:DB00964'
p2806
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2807
sg24
Nsg25
Nsg26
S'Iopidine'
p2808
sg28
Nsg29
S'Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.| \r'
p2809
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p2810
sa(dp2811
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p2812
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p2813
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2814
sg24
Nsg25
Nsg26
S'Irbesartan'
p2815
sg28
Nsg29
S'Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| \r'
p2816
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALISKIREN'
p2817
sa(dp2818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00822'
p2819
sg5
S'http://bio2rdf.org/drugbank:DB01247'
p2820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2821
sg24
Nsg25
Nsg26
S'ISOCARBOXAZID'
p2822
sg28
Nsg29
S'Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| \r'
p2823
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Antabuse'
p2824
sa(dp2825
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2826
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2827
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2828
sg24
Nsg25
Nsg26
S'Isoflurane'
p2829
sg28
Nsg29
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p2830
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p2831
sa(dp2832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p2833
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2835
sg24
Nsg25
Nsg26
S'Isoflurane'
p2836
sg28
Nsg29
S'Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p2837
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p2838
sa(dp2839
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01135'
p2840
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p2841
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2842
sg24
Nsg25
Nsg26
S'Isoflurane'
p2843
sg28
Nsg29
S'Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.| \r'
p2844
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nuromax'
p2845
sa(dp2846
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p2847
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2848
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2849
sg24
Nsg25
Nsg26
S'ISONIAZID'
p2850
sg28
Nsg29
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p2851
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p2852
sa(dp2853
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p2854
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p2855
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2856
sg24
Nsg25
Nsg26
S'ISONIAZID'
p2857
sg28
Nsg29
S'Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| \r'
p2858
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p2859
sa(dp2860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00870'
p2861
sg5
S'http://bio2rdf.org/drugbank:DB00411'
p2862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2863
sg24
Nsg25
Nsg26
S'Isopto Carbachol'
p2864
sg28
Nsg29
S'Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| \r'
p2865
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Suprofen'
p2866
sa(dp2867
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p2868
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2869
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2870
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2871
sg28
Nsg29
S'Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| \r'
p2872
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALISKIREN'
p2873
sa(dp2874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p2875
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2877
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2878
sg28
Nsg29
S'Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.| \r'
p2879
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALOSETRON'
p2880
sa(dp2881
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p2882
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2883
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2884
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2885
sg28
Nsg29
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p2886
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p2887
sa(dp2888
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p2889
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2890
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2891
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2892
sg28
Nsg29
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| \r'
p2893
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p2894
sa(dp2895
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2896
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2897
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2898
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2899
sg28
Nsg29
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p2900
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p2901
sa(dp2902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p2903
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2905
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2906
sg28
Nsg29
S'Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p2907
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p2908
sa(dp2909
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p2910
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2911
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2912
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2913
sg28
Nsg29
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p2914
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p2915
sa(dp2916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01012'
p2917
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2919
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2920
sg28
Nsg29
S'Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| \r'
p2921
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CINACALCET'
p2922
sa(dp2923
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2924
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2925
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p2926
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2927
sg28
Nsg29
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| \r'
p2928
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2929
sa(dp2930
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2931
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2932
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2933
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2934
sg28
Nsg29
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| \r'
p2935
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2936
sa(dp2937
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p2938
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2939
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2940
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2941
sg28
Nsg29
S'Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| \r'
p2942
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p2943
sa(dp2944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p2945
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p2947
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2948
sg28
Nsg29
S'When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.| \r'
p2949
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'COUMARIN'
p2950
sa(dp2951
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p2952
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2953
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p2954
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2955
sg28
Nsg29
S'Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| \r'
p2956
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p2957
sa(dp2958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01259'
p2959
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2961
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2962
sg28
Nsg29
S'Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| \r'
p2963
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LAPATINIB'
p2964
sa(dp2965
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00455'
p2966
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2967
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2968
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2969
sg28
Nsg29
S'After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.| \r'
p2970
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'LORATADINE'
p2971
sa(dp2972
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p2973
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2974
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2975
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2976
sg28
Nsg29
S'Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p2977
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p2978
sa(dp2979
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p2980
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2981
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2982
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2983
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p2984
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p2985
sa(dp2986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p2987
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2989
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2990
sg28
Nsg29
S'Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | \r'
p2991
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p2992
sa(dp2993
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00764'
p2994
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p2995
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p2996
sg24
Nsg25
Nsg26
S'Ketoconazole'
p2997
sg28
Nsg29
S'However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.| \r'
p2998
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mometasone Furoate'
p2999
sa(dp3000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00910'
p3001
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3003
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3004
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3005
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PARICALCITOL'
p3006
sa(dp3007
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00296'
p3008
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3009
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3010
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3011
sg28
Nsg29
S'Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.| \r'
p3012
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ropivacaine'
p3013
sa(dp3014
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3015
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3016
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3017
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3018
sg28
Nsg29
S'Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| \r'
p3019
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p3020
sa(dp3021
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01036'
p3022
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3023
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3024
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3025
sg28
Nsg29
S'CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). | \r'
p3026
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLTERODINE'
p3027
sa(dp3028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01157'
p3029
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3031
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3032
sg28
Nsg29
S'Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | \r'
p3033
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIMETREXATE'
p3034
sa(dp3035
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p3036
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3037
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3038
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3039
sg28
Nsg29
S'Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.| \r'
p3040
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p3041
sa(dp3042
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3043
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3044
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3045
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3046
sg28
Nsg29
S'Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.| \r'
p3047
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Videx'
p3048
sa(dp3049
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p3050
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3051
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3052
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3053
sg28
Nsg29
S'Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.| \r'
p3054
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p3055
sa(dp3056
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p3057
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3058
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3059
sg24
Nsg25
Nsg26
S'Ketoconazole'
p3060
sg28
Nsg29
S'Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| \r'
p3061
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALEPLON'
p3062
sa(dp3063
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3064
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p3065
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3066
sg24
Nsg25
Nsg26
S'Lamivudine'
p3067
sg28
Nsg29
S'Therefore, use of lamivudine in combination with zalcitabine is not recommended| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| \r'
p3068
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p3069
sa(dp3070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3071
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p3072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3073
sg24
Nsg25
Nsg26
S'Lamivudine'
p3074
sg28
Nsg29
S'Therefore, use of lamivudine in combination with zalcitabine is not recommended| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| \r'
p3075
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p3076
sa(dp3077
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p3078
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p3079
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3080
sg24
Nsg25
Nsg26
S'Lansoprazole'
p3081
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p3082
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p3083
sa(dp3084
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3085
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p3086
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3087
sg24
Nsg25
Nsg26
S'Lansoprazole'
p3088
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p3089
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3090
sa(dp3091
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3092
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p3093
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3094
sg24
Nsg25
Nsg26
S'Lansoprazole'
p3095
sg28
Nsg29
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p3096
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p3097
sa(dp3098
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00072'
p3099
sg5
S'http://bio2rdf.org/drugbank:DB01259'
p3100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3101
sg24
Nsg25
Nsg26
S'LAPATINIB'
p3102
sg28
Nsg29
S'In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| \r'
p3103
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Herceptin'
p3104
sa(dp3105
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3106
sg5
S'http://bio2rdf.org/drugbank:DB00854'
p3107
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3108
sg24
Nsg25
Nsg26
S'Levo-Dromoran'
p3109
sg28
Nsg29
S'Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| \r'
p3110
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p3111
sa(dp3112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00286'
p3113
sg5
S'http://bio2rdf.org/drugbank:DB00451'
p3114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3115
sg24
Nsg25
Nsg26
S'LEVOTHYROXINE'
p3116
sg28
Nsg29
S'In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.| \r'
p3117
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Estrogens'
p3118
sa(dp3119
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p3120
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p3121
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3122
sg24
Nsg25
Nsg26
S'Levsin'
p3123
sg28
Nsg29
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p3124
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p3125
sa(dp3126
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3127
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p3128
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3129
sg24
Nsg25
Nsg26
S'Lodine'
p3130
sg28
Nsg29
S'however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| \r'
p3131
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3132
sa(dp3133
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3134
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p3135
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3136
sg24
Nsg25
Nsg26
S'Lodine'
p3137
sg28
Nsg29
S'however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| \r'
p3138
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3139
sa(dp3140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3141
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p3142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3143
sg24
Nsg25
Nsg26
S'Lodine'
p3144
sg28
Nsg29
S'Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| \r'
p3145
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3146
sa(dp3147
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p3148
sg5
S'http://bio2rdf.org/drugbank:DB01601'
p3149
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3150
sg24
Nsg25
Nsg26
S'LOPINAVIR'
p3151
sg28
Nsg29
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p3152
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sustiva'
p3153
sa(dp3154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p3155
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3157
sg24
Nsg25
Nsg26
S'Mazindol'
p3158
sg28
Nsg29
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p3159
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p3160
sa(dp3161
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p3162
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3163
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3164
sg24
Nsg25
Nsg26
S'Mazindol'
p3165
sg28
Nsg29
S'Mazindol may reduce the effects of guanethidine (Ismelin). | \r'
p3166
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ismelin'
p3167
sa(dp3168
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p3169
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3170
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3171
sg24
Nsg25
Nsg26
S'Mazindol'
p3172
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3173
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISOCARBOXAZID'
p3174
sa(dp3175
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01247'
p3176
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3177
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3178
sg24
Nsg25
Nsg26
S'Mazindol'
p3179
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3180
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Marplan'
p3181
sa(dp3182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p3183
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3185
sg24
Nsg25
Nsg26
S'Mazindol'
p3186
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3187
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nardil'
p3188
sa(dp3189
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p3190
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3191
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3192
sg24
Nsg25
Nsg26
S'Mazindol'
p3193
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3194
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Parnate'
p3195
sa(dp3196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00780'
p3197
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3199
sg24
Nsg25
Nsg26
S'Mazindol'
p3200
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3201
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENELZINE'
p3202
sa(dp3203
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00752'
p3204
sg5
S'http://bio2rdf.org/drugbank:DB00579'
p3205
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3206
sg24
Nsg25
Nsg26
S'Mazindol'
p3207
sg28
Nsg29
S'You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | \r'
p3208
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tranylcypromine'
p3209
sa(dp3210
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3211
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p3212
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3213
sg24
Nsg25
Nsg26
S'Melatonin'
p3214
sg28
Nsg29
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p3215
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3216
sa(dp3217
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3218
sg5
S'http://bio2rdf.org/drugbank:DB01065'
p3219
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3220
sg24
Nsg25
Nsg26
S'Melatonin'
p3221
sg28
Nsg29
S'Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| \r'
p3222
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p3223
sa(dp3224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3225
sg5
S'http://bio2rdf.org/drugbank:DB00814'
p3226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3227
sg24
Nsg25
Nsg26
S'Meloxicam'
p3228
sg28
Nsg29
S'however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. | \r'
p3229
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3230
sa(dp3231
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3232
sg5
S'http://bio2rdf.org/drugbank:DB00454'
p3233
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3234
sg24
Nsg25
Nsg26
S'MEPERIDINE'
p3235
sg28
Nsg29
S'Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). | \r'
p3236
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p3237
sa(dp3238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p3239
sg5
S'http://bio2rdf.org/drugbank:DB00760'
p3240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3241
sg24
Nsg25
Nsg26
S'Meropenem'
p3242
sg28
Nsg29
S'There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| \r'
p3243
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALPROIC ACID'
p3244
sa(dp3245
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3246
sg5
S'http://bio2rdf.org/drugbank:DB00331'
p3247
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3248
sg24
Nsg25
Nsg26
S'METFORMIN'
p3249
sg28
Nsg29
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p3250
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p3251
sa(dp3252
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01626'
p3253
sg5
S'http://bio2rdf.org/drugbank:DB01577'
p3254
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3255
sg24
Nsg25
Nsg26
S'METHAMPHETAMINE'
p3256
sg28
Nsg29
S'Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. | \r'
p3257
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PARGYLINE'
p3258
sa(dp3259
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3260
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p3261
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3262
sg24
Nsg25
Nsg26
S'METHYLPREDNISOLONE'
p3263
sg28
Nsg29
S'The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| \r'
p3264
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p3265
sa(dp3266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3267
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p3268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3269
sg24
Nsg25
Nsg26
S'METHYLPREDNISOLONE'
p3270
sg28
Nsg29
S'Methylprednisolone may increase the clearance of chronic high dose aspirin. | \r'
p3271
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3272
sa(dp3273
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3274
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3275
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3276
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p3277
sg28
Nsg29
S'Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. | \r'
p3278
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p3279
sa(dp3280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p3281
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3283
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p3284
sg28
Nsg29
S'Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| \r'
p3285
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Apokyn'
p3286
sa(dp3287
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p3288
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3289
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3290
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p3291
sg28
Nsg29
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p3292
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p3293
sa(dp3294
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01186'
p3295
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3296
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3297
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p3298
sg28
Nsg29
S'Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); | \r'
p3299
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Permax'
p3300
sa(dp3301
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p3302
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p3303
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3304
sg24
Nsg25
Nsg26
S'METOCLOPRAMIDE'
p3305
sg28
Nsg29
S'Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. | \r'
p3306
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mirapex'
p3307
sa(dp3308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p3309
sg5
S'http://bio2rdf.org/drugbank:DB00916'
p3310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3311
sg24
Nsg25
Nsg26
S'METRONIDAZOLE'
p3312
sg28
Nsg29
S'Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. | \r'
p3313
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'COUMARIN'
p3314
sa(dp3315
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p3316
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3317
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3318
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p3319
sg28
Nsg29
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p3320
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p3321
sa(dp3322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p3323
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3325
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p3326
sg28
Nsg29
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p3327
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p3328
sa(dp3329
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p3330
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3331
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3332
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p3333
sg28
Nsg29
S'This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | \r'
p3334
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p3335
sa(dp3336
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p3337
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p3338
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3339
sg24
Nsg25
Nsg26
S'MIDAZOLAM'
p3340
sg28
Nsg29
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p3341
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p3342
sa(dp3343
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p3344
sg5
S'http://bio2rdf.org/drugbank:DB00235'
p3345
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3346
sg24
Nsg25
Nsg26
S'MILRINONE'
p3347
sg28
Nsg29
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p3348
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANAGRELIDE'
p3349
sa(dp3350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p3351
sg5
S'http://bio2rdf.org/drugbank:DB00350'
p3352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3353
sg24
Nsg25
Nsg26
S'MINOXIDIL'
p3354
sg28
Nsg29
S'Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. | \r'
p3355
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p3356
sa(dp3357
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p3358
sg5
S'http://bio2rdf.org/drugbank:DB01226'
p3359
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p3360
sg24
Nsg25
Nsg26
S'Mivacron'
p3361
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | \r'
p3362
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Colistin'
p3363
sa(dp3364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p3365
sg5
S'http://bio2rdf.org/drugbank:DB01171'
p3366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3367
sg24
Nsg25
Nsg26
S'MOCLOBEMIDE'
p3368
sg28
Nsg29
S'Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| \r'
p3369
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALMOTRIPTAN'
p3370
sa(dp3371
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p3372
sg5
S'http://bio2rdf.org/drugbank:DB00828'
p3373
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3374
sg24
Nsg25
Nsg26
S'Monurol'
p3375
sg28
Nsg29
S'Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| \r'
p3376
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p3377
sa(dp3378
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p3379
sg5
S'http://bio2rdf.org/drugbank:DB01024'
p3380
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3381
sg24
Nsg25
Nsg26
S'Myfortic'
p3382
sg28
Nsg29
S'Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | \r'
p3383
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p3384
sa(dp3385
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3386
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3387
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3388
sg24
Nsg25
Nsg26
S'Nabilone'
p3389
sg28
Nsg29
S'Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3390
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p3391
sa(dp3392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3393
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3395
sg24
Nsg25
Nsg26
S'Nabilone'
p3396
sg28
Nsg29
S'Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3397
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p3398
sa(dp3399
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p3400
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p3401
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3402
sg24
Nsg25
Nsg26
S'Nabilone'
p3403
sg28
Nsg29
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p3404
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p3405
sa(dp3406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3407
sg5
S'http://bio2rdf.org/drugbank:DB00844'
p3408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3409
sg24
Nsg25
Nsg26
S'NALBUPHINE'
p3410
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3411
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p3412
sa(dp3413
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01042'
p3414
sg5
S'http://bio2rdf.org/drugbank:DB00779'
p3415
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3416
sg24
Nsg25
Nsg26
S'NALIDIXIC ACID'
p3417
sg28
Nsg29
S'DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  | \r'
p3418
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MELPHALAN'
p3419
sa(dp3420
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00659'
p3421
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p3422
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3423
sg24
Nsg25
Nsg26
S'NALTREXONE'
p3424
sg28
Nsg29
S'Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| \r'
p3425
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACAMPROSATE'
p3426
sa(dp3427
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3428
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p3429
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3430
sg24
Nsg25
Nsg26
S'NAPROXEN'
p3431
sg28
Nsg29
S'Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| \r'
p3432
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3433
sa(dp3434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3435
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p3436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3437
sg24
Nsg25
Nsg26
S'NEFAZODONE'
p3438
sg28
Nsg29
S'Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p3439
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p3440
sa(dp3441
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p3442
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p3443
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3444
sg24
Nsg25
Nsg26
S'NELFINAVIR'
p3445
sg28
Nsg29
S'Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| \r'
p3446
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p3447
sa(dp3448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p3449
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p3450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3451
sg24
Nsg25
Nsg26
S'NELFINAVIR'
p3452
sg28
Nsg29
S'therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.| \r'
p3453
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIDANOSINE'
p3454
sa(dp3455
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3456
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p3457
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3458
sg24
Nsg25
Nsg26
S'NELFINAVIR'
p3459
sg28
Nsg29
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p3460
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p3461
sa(dp3462
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p3463
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p3464
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3465
sg24
Nsg25
Nsg26
S'Nimbex'
p3466
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p3467
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Colistin'
p3468
sa(dp3469
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p3470
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p3471
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3472
sg24
Nsg25
Nsg26
S'Nimbex'
p3473
sg28
Nsg29
S'Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.| The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.| \r'
p3474
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p3475
sa(dp3476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00435'
p3477
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p3478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3479
sg24
Nsg25
Nsg26
S'NITROGLYCERIN'
p3480
sg28
Nsg29
S'Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| \r'
p3481
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'INOmax'
p3482
sa(dp3483
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p3484
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3485
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3486
sg24
Nsg25
Nsg26
S'Nizoral'
p3487
sg28
Nsg29
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p3488
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p3489
sa(dp3490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p3491
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p3492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3493
sg24
Nsg25
Nsg26
S'Nizoral'
p3494
sg28
Nsg29
S'Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| \r'
p3495
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p3496
sa(dp3497
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p3498
sg5
S'http://bio2rdf.org/drugbank:DB00717'
p3499
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3500
sg24
Nsg25
Nsg26
S'NORETHINDRONE'
p3501
sg28
Nsg29
S'The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| \r'
p3502
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GABAPENTIN'
p3503
sa(dp3504
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p3505
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p3506
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3507
sg24
Nsg25
Nsg26
S'NORFLOXACIN'
p3508
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p3509
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p3510
sa(dp3511
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00803'
p3512
sg5
S'http://bio2rdf.org/drugbank:DB01135'
p3513
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3514
sg24
Nsg25
Nsg26
S'Nuromax'
p3515
sg28
Nsg29
S'Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| \r'
p3516
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Colistin'
p3517
sa(dp3518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00450'
p3519
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p3520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3521
sg24
Nsg25
Nsg26
S'OUABAIN'
p3522
sg28
Nsg29
S'Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.| \r'
p3523
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DROPERIDOL'
p3524
sa(dp3525
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00692'
p3526
sg5
S'http://bio2rdf.org/drugbank:DB01092'
p3527
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3528
sg24
Nsg25
Nsg26
S'OUABAIN'
p3529
sg28
Nsg29
S'When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. | \r'
p3530
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENTOLAMINE'
p3531
sa(dp3532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3533
sg5
S'http://bio2rdf.org/drugbank:DB03585'
p3534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3535
sg24
Nsg25
Nsg26
S'Oxyphenbutazone'
p3536
sg28
Nsg29
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3537
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3538
sa(dp3539
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00115'
p3540
sg5
S'http://bio2rdf.org/drugbank:DB00233'
p3541
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3542
sg24
Nsg25
Nsg26
S'para-aminosalicylic acid'
p3543
sg28
Nsg29
S'Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| \r'
p3544
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Vitamin B12'
p3545
sa(dp3546
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p3547
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3548
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3549
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p3550
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3551
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p3552
sa(dp3553
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3554
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3555
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3556
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p3557
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3558
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p3559
sa(dp3560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p3561
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3563
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p3564
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3565
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p3566
sa(dp3567
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p3568
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3569
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3570
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p3571
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3572
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p3573
sa(dp3574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p3575
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3577
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p3578
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3579
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p3580
sa(dp3581
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p3582
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p3583
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3584
sg24
Nsg25
Nsg26
S'PARICALCITOL'
p3585
sg28
Nsg29
S'A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | \r'
p3586
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VORICONAZOLE'
p3587
sa(dp3588
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p3589
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3590
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3591
sg24
Nsg25
Nsg26
S'PAROXETINE'
p3592
sg28
Nsg29
S'Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| \r'
p3593
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ARIPIPRAZOLE'
p3594
sa(dp3595
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p3596
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3597
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3598
sg24
Nsg25
Nsg26
S'PAROXETINE'
p3599
sg28
Nsg29
S'In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| \r'
p3600
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATOMOXETINE'
p3601
sa(dp3602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p3603
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3605
sg24
Nsg25
Nsg26
S'PAROXETINE'
p3606
sg28
Nsg29
S'Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| \r'
p3607
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p3608
sa(dp3609
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p3610
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3611
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3612
sg24
Nsg25
Nsg26
S'PAROXETINE'
p3613
sg28
Nsg29
S'Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| \r'
p3614
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DULOXETINE'
p3615
sa(dp3616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p3617
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p3618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3619
sg24
Nsg25
Nsg26
S'PAROXETINE'
p3620
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p3621
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p3622
sa(dp3623
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p3624
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p3625
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3626
sg24
Nsg25
Nsg26
S'Peganone'
p3627
sg28
Nsg29
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p3628
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENACEMIDE'
p3629
sa(dp3630
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p3631
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p3632
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3633
sg24
Nsg25
Nsg26
S'Peganone'
p3634
sg28
Nsg29
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p3635
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Phenurone'
p3636
sa(dp3637
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3638
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p3639
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3640
sg24
Nsg25
Nsg26
S'PENTAMIDINE'
p3641
sg28
Nsg29
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p3642
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p3643
sa(dp3644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p3645
sg5
S'http://bio2rdf.org/drugbank:DB00738'
p3646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3647
sg24
Nsg25
Nsg26
S'PENTAMIDINE'
p3648
sg28
Nsg29
S'Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| \r'
p3649
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HIVID'
p3650
sa(dp3651
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p3652
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p3653
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3654
sg24
Nsg25
Nsg26
S'Pentazocine'
p3655
sg28
Nsg29
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p3656
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Levo-Dromoran'
p3657
sa(dp3658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00792'
p3659
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p3660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3661
sg24
Nsg25
Nsg26
S'Pentazocine'
p3662
sg28
Nsg29
S'Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. | \r'
p3663
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIPELENNAMINE'
p3664
sa(dp3665
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3666
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3667
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3668
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3669
sg28
Nsg29
S'Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| \r'
p3670
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3671
sa(dp3672
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p3673
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3674
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3675
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3676
sg28
Nsg29
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p3677
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p3678
sa(dp3679
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p3680
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3681
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3682
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3683
sg28
Nsg29
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p3684
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CALCITRIOL'
p3685
sa(dp3686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p3687
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3689
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3690
sg28
Nsg29
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p3691
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONAZEPAM'
p3692
sa(dp3693
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p3694
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3695
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3696
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3697
sg28
Nsg29
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p3698
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p3699
sa(dp3700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p3701
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3703
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3704
sg28
Nsg29
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| \r'
p3705
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EXEMESTANE'
p3706
sa(dp3707
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p3708
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3709
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3710
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3711
sg28
Nsg29
S'Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| \r'
p3712
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Fenoprofen'
p3713
sa(dp3714
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p3715
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3716
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3717
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3718
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p3719
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p3720
sa(dp3721
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p3722
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3723
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3724
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3725
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p3726
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p3727
sa(dp3728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p3729
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3731
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3732
sg28
Nsg29
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p3733
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p3734
sa(dp3735
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00834'
p3736
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3737
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3738
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3739
sg28
Nsg29
S'John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | \r'
p3740
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIFEPRISTONE'
p3741
sa(dp3742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p3743
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3745
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3746
sg28
Nsg29
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p3747
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MONTELUKAST'
p3748
sa(dp3749
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p3750
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3751
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3752
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3753
sg28
Nsg29
S'When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| \r'
p3754
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nalfon'
p3755
sa(dp3756
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p3757
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p3758
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3759
sg24
Nsg25
Nsg26
S'PHENOBARBITAL'
p3760
sg28
Nsg29
S'The increase of phenobarbital level, however, is small (15%) when given with Trileptal.| \r'
p3761
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Trileptal'
p3762
sa(dp3763
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3764
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p3765
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3766
sg24
Nsg25
Nsg26
S'PHENYLBUTAZONE'
p3767
sg28
Nsg29
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p3768
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3769
sa(dp3770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p3771
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p3772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3773
sg24
Nsg25
Nsg26
S'PHENYLBUTAZONE'
p3774
sg28
Nsg29
S'Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| \r'
p3775
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Etodolac'
p3776
sa(dp3777
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p3778
sg5
S'http://bio2rdf.org/drugbank:DB00388'
p3779
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3780
sg24
Nsg25
Nsg26
S'PHENYLEPHRINE'
p3781
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p3782
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p3783
sa(dp3784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p3785
sg5
S'http://bio2rdf.org/drugbank:DB01057'
p3786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3787
sg24
Nsg25
Nsg26
S'Phospholine Iodide'
p3788
sg28
Nsg29
S'Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| \r'
p3789
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p3790
sa(dp3791
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p3792
sg5
S'http://bio2rdf.org/drugbank:DB00981'
p3793
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3794
sg24
Nsg25
Nsg26
S'PHYSOSTIGMINE'
p3795
sg28
Nsg29
S"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. | \r"
p3796
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p3797
sa(dp3798
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01254'
p3799
sg5
S'http://bio2rdf.org/drugbank:DB01100'
p3800
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3801
sg24
Nsg25
Nsg26
S'PIMOZIDE'
p3802
sg28
Nsg29
S'Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| \r'
p3803
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sprycel'
p3804
sa(dp3805
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p3806
sg5
S'http://bio2rdf.org/drugbank:DB00319'
p3807
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3808
sg24
Nsg25
Nsg26
S'PIPERACILLIN ANHYDROUS'
p3809
sg28
Nsg29
S'In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| \r'
p3810
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VECURONIUM'
p3811
sa(dp3812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p3813
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p3814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3815
sg24
Nsg25
Nsg26
S'Pletal'
p3816
sg28
Nsg29
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p3817
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p3818
sa(dp3819
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p3820
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p3821
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3822
sg24
Nsg25
Nsg26
S'Ponstel'
p3823
sg28
Nsg29
S'Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p3824
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p3825
sa(dp3826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p3827
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p3828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3829
sg24
Nsg25
Nsg26
S'Posicor'
p3830
sg28
Nsg29
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p3831
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p3832
sa(dp3833
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p3834
sg5
S'http://bio2rdf.org/drugbank:DB01388'
p3835
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3836
sg24
Nsg25
Nsg26
S'Posicor'
p3837
sg28
Nsg29
S"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | \r"
p3838
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p3839
sa(dp3840
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p3841
sg5
S'http://bio2rdf.org/drugbank:DB00733'
p3842
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3843
sg24
Nsg25
Nsg26
S'PRALIDOXIME'
p3844
sg28
Nsg29
S'When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| \r'
p3845
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atropine'
p3846
sa(dp3847
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p3848
sg5
S'http://bio2rdf.org/drugbank:DB00457'
p3849
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3850
sg24
Nsg25
Nsg26
S'PRAZOSIN'
p3851
sg28
Nsg29
S'ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. | \r'
p3852
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p3853
sa(dp3854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00421'
p3855
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3857
sg24
Nsg25
Nsg26
S'Prinivil'
p3858
sg28
Nsg29
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p3859
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Spironolactone'
p3860
sa(dp3861
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p3862
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p3863
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3864
sg24
Nsg25
Nsg26
S'Prinivil'
p3865
sg28
Nsg29
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p3866
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAMTERENE'
p3867
sa(dp3868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00787'
p3869
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3871
sg24
Nsg25
Nsg26
S'PROBENECID'
p3872
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| \r'
p3873
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACYCLOVIR'
p3874
sa(dp3875
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00642'
p3876
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3877
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3878
sg24
Nsg25
Nsg26
S'PROBENECID'
p3879
sg28
Nsg29
S'Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. | \r'
p3880
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alimta'
p3881
sa(dp3882
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p3883
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3884
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3885
sg24
Nsg25
Nsg26
S'PROBENECID'
p3886
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3887
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMINOSALICYLIC ACID'
p3888
sa(dp3889
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p3890
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3891
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3892
sg24
Nsg25
Nsg26
S'PROBENECID'
p3893
sg28
Nsg29
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p3894
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPICILLIN'
p3895
sa(dp3896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3897
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3899
sg24
Nsg25
Nsg26
S'PROBENECID'
p3900
sg28
Nsg29
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3901
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Bumetanide'
p3902
sa(dp3903
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3904
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3905
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p3906
sg24
Nsg25
Nsg26
S'PROBENECID'
p3907
sg28
Nsg29
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3908
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Bumetanide'
p3909
sa(dp3910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p3911
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3913
sg24
Nsg25
Nsg26
S'PROBENECID'
p3914
sg28
Nsg29
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3915
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Bumetanide'
p3916
sa(dp3917
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00535'
p3918
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3919
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3920
sg24
Nsg25
Nsg26
S'PROBENECID'
p3921
sg28
Nsg29
S'Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| \r'
p3922
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CEFDINIR'
p3923
sa(dp3924
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01066'
p3925
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3926
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3927
sg24
Nsg25
Nsg26
S'PROBENECID'
p3928
sg28
Nsg29
S'Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.| \r'
p3929
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cefditoren Pivoxil'
p3930
sa(dp3931
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p3932
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3933
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3934
sg24
Nsg25
Nsg26
S'PROBENECID'
p3935
sg28
Nsg29
S'Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| \r'
p3936
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p3937
sa(dp3938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p3939
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3941
sg24
Nsg25
Nsg26
S'PROBENECID'
p3942
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3943
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOFIBRATE'
p3944
sa(dp3945
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01147'
p3946
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3947
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3948
sg24
Nsg25
Nsg26
S'PROBENECID'
p3949
sg28
Nsg29
S'This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.| \r'
p3950
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOXACILLIN'
p3951
sa(dp3952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p3953
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3955
sg24
Nsg25
Nsg26
S'PROBENECID'
p3956
sg28
Nsg29
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p3957
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERTAPENEM'
p3958
sa(dp3959
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00303'
p3960
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3961
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3962
sg24
Nsg25
Nsg26
S'PROBENECID'
p3963
sg28
Nsg29
S'When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| \r'
p3964
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERTAPENEM'
p3965
sa(dp3966
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00927'
p3967
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3968
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3969
sg24
Nsg25
Nsg26
S'PROBENECID'
p3970
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p3971
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FAMOTIDINE'
p3972
sa(dp3973
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p3974
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3975
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p3976
sg24
Nsg25
Nsg26
S'PROBENECID'
p3977
sg28
Nsg29
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p3978
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Meropenem'
p3979
sa(dp3980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00760'
p3981
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3983
sg24
Nsg25
Nsg26
S'PROBENECID'
p3984
sg28
Nsg29
S'Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | \r'
p3985
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Meropenem'
p3986
sa(dp3987
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p3988
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3989
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3990
sg24
Nsg25
Nsg26
S'PROBENECID'
p3991
sg28
Nsg29
S'Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| \r'
p3992
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NAPROXEN'
p3993
sa(dp3994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p3995
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p3996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p3997
sg24
Nsg25
Nsg26
S'PROBENECID'
p3998
sg28
Nsg29
S'Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| \r'
p3999
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p4000
sa(dp4001
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p4002
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4003
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4004
sg24
Nsg25
Nsg26
S'PROBENECID'
p4005
sg28
Nsg29
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p4006
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAH'
p4007
sa(dp4008
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00345'
p4009
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4010
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4011
sg24
Nsg25
Nsg26
S'PROBENECID'
p4012
sg28
Nsg29
S'Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| \r'
p4013
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAH'
p4014
sa(dp4015
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00299'
p4016
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4017
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4018
sg24
Nsg25
Nsg26
S'PROBENECID'
p4019
sg28
Nsg29
S'Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| \r'
p4020
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENCICLOVIR'
p4021
sa(dp4022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00319'
p4023
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4025
sg24
Nsg25
Nsg26
S'PROBENECID'
p4026
sg28
Nsg29
S'Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.| \r'
p4027
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pipracil'
p4028
sa(dp4029
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p4030
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4031
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4032
sg24
Nsg25
Nsg26
S'PROBENECID'
p4033
sg28
Nsg29
S'Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| \r'
p4034
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALCITABINE'
p4035
sa(dp4036
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p4037
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p4038
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4039
sg24
Nsg25
Nsg26
S'PROBENECID'
p4040
sg28
Nsg29
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p4041
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZIDOVUDINE'
p4042
sa(dp4043
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00762'
p4044
sg5
S'http://bio2rdf.org/drugbank:DB00433'
p4045
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4046
sg24
Nsg25
Nsg26
S'PROCHLORPERAZINE'
p4047
sg28
Nsg29
S'The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).| \r'
p4048
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Camptosar'
p4049
sa(dp4050
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00851'
p4051
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p4052
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4053
sg24
Nsg25
Nsg26
S'Proleukin'
p4054
sg28
Nsg29
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p4055
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dacarbazine'
p4056
sa(dp4057
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p4058
sg5
S'http://bio2rdf.org/drugbank:DB00041'
p4059
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4060
sg24
Nsg25
Nsg26
S'Proleukin'
p4061
sg28
Nsg29
S'Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| \r'
p4062
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tamoxifen'
p4063
sa(dp4064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4065
sg5
S'http://bio2rdf.org/drugbank:DB00782'
p4066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4067
sg24
Nsg25
Nsg26
S'PROPANTHELINE'
p4068
sg28
Nsg29
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p4069
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4070
sa(dp4071
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00211'
p4072
sg5
S'http://bio2rdf.org/drugbank:DB00852'
p4073
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4074
sg24
Nsg25
Nsg26
S'PSEUDOEPHEDRINE'
p4075
sg28
Nsg29
S'The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | \r'
p4076
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ProAmatine'
p4077
sa(dp4078
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00352'
p4079
sg5
S'http://bio2rdf.org/drugbank:DB01033'
p4080
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4081
sg24
Nsg25
Nsg26
S'Purinethol'
p4082
sg28
Nsg29
S'There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | \r'
p4083
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tabloid'
p4084
sa(dp4085
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p4086
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p4087
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4088
sg24
Nsg25
Nsg26
S'PYRIDOXINE'
p4089
sg28
Nsg29
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p4090
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Hexalen'
p4091
sa(dp4092
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p4093
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p4094
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4095
sg24
Nsg25
Nsg26
S'QUININE'
p4096
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p4097
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p4098
sa(dp4099
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4100
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p4101
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4102
sg24
Nsg25
Nsg26
S'QUININE'
p4103
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p4104
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p4105
sa(dp4106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4107
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p4108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4109
sg24
Nsg25
Nsg26
S'Remeron'
p4110
sg28
Nsg29
S'However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. | \r'
p4111
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p4112
sa(dp4113
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4114
sg5
S'http://bio2rdf.org/drugbank:DB00370'
p4115
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4116
sg24
Nsg25
Nsg26
S'Remeron'
p4117
sg28
Nsg29
S'However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. | \r'
p4118
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p4119
sa(dp4120
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p4121
sg5
S'http://bio2rdf.org/drugbank:DB00206'
p4122
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4123
sg24
Nsg25
Nsg26
S'RESERPINE'
p4124
sg28
Nsg29
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p4125
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zebeta'
p4126
sa(dp4127
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p4128
sg5
S'http://bio2rdf.org/drugbank:DB00162'
p4129
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4130
sg24
Nsg25
Nsg26
S'RETINOL'
p4131
sg28
Nsg29
S'Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| \r'
p4132
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ACITRETIN'
p4133
sa(dp4134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p4135
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p4136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4137
sg24
Nsg25
Nsg26
S'RIBAVIRIN'
p4138
sg28
Nsg29
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p4139
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p4140
sa(dp4141
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p4142
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p4143
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4144
sg24
Nsg25
Nsg26
S'RIBAVIRIN'
p4145
sg28
Nsg29
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p4146
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZIDOVUDINE'
p4147
sa(dp4148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p4149
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4151
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p4152
sg28
Nsg29
S'Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| \r'
p4153
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Crixivan'
p4154
sa(dp4155
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p4156
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4157
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4158
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p4159
sg28
Nsg29
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p4160
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p4161
sa(dp4162
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4163
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4164
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4165
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p4166
sg28
Nsg29
S'Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. | \r'
p4167
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p4168
sa(dp4169
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4170
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4171
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4172
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p4173
sg28
Nsg29
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p4174
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p4175
sa(dp4176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4177
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p4178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4179
sg24
Nsg25
Nsg26
S'RIFABUTIN'
p4180
sg28
Nsg29
S'It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| \r'
p4181
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p4182
sa(dp4183
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p4184
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4185
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4186
sg24
Nsg25
Nsg26
S'Rifampin'
p4187
sg28
Nsg29
S'Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. | Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. | \r'
p4188
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPRENAVIR'
p4189
sa(dp4190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p4191
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4193
sg24
Nsg25
Nsg26
S'Rifampin'
p4194
sg28
Nsg29
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p4195
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'BEXAROTENE'
p4196
sa(dp4197
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00520'
p4198
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4199
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4200
sg24
Nsg25
Nsg26
S'Rifampin'
p4201
sg28
Nsg29
S'Patients on rifampin should receive 70 mg of CANCIDAS daily.| \r'
p4202
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cancidas'
p4203
sa(dp4204
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p4205
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4206
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4207
sg24
Nsg25
Nsg26
S'Rifampin'
p4208
sg28
Nsg29
S'Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| \r'
p4209
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLOZAPINE'
p4210
sa(dp4211
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p4212
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4213
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4214
sg24
Nsg25
Nsg26
S'Rifampin'
p4215
sg28
Nsg29
S'Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. | \r'
p4216
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Diflucan'
p4217
sa(dp4218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4219
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4221
sg24
Nsg25
Nsg26
S'Rifampin'
p4222
sg28
Nsg29
S'Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| \r'
p4223
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4224
sa(dp4225
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p4226
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4227
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4228
sg24
Nsg25
Nsg26
S'Rifampin'
p4229
sg28
Nsg29
S'Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| \r'
p4230
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'EFAVIRENZ'
p4231
sa(dp4232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p4233
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4235
sg24
Nsg25
Nsg26
S'Rifampin'
p4236
sg28
Nsg29
S'Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| \r'
p4237
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Gleevec'
p4238
sa(dp4239
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p4240
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4241
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4242
sg24
Nsg25
Nsg26
S'Rifampin'
p4243
sg28
Nsg29
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p4244
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p4245
sa(dp4246
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p4247
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4248
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4249
sg24
Nsg25
Nsg26
S'Rifampin'
p4250
sg28
Nsg29
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| \r'
p4251
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'HALOPERIDOL'
p4252
sa(dp4253
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4254
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4255
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4256
sg24
Nsg25
Nsg26
S'Rifampin'
p4257
sg28
Nsg29
S'Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| \r'
p4258
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4259
sa(dp4260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p4261
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4263
sg24
Nsg25
Nsg26
S'Rifampin'
p4264
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p4265
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p4266
sa(dp4267
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p4268
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4269
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4270
sg24
Nsg25
Nsg26
S'Rifampin'
p4271
sg28
Nsg29
S'Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | \r'
p4272
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p4273
sa(dp4274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00379'
p4275
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4277
sg24
Nsg25
Nsg26
S'Rifampin'
p4278
sg28
Nsg29
S'When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | \r'
p4279
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mexitil'
p4280
sa(dp4281
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p4282
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4283
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4284
sg24
Nsg25
Nsg26
S'Rifampin'
p4285
sg28
Nsg29
S'Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | \r'
p4286
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p4287
sa(dp4288
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00471'
p4289
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4290
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4291
sg24
Nsg25
Nsg26
S'Rifampin'
p4292
sg28
Nsg29
S'It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| \r'
p4293
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MONTELUKAST'
p4294
sa(dp4295
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00717'
p4296
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4297
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4298
sg24
Nsg25
Nsg26
S'Rifampin'
p4299
sg28
Nsg29
S'Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| \r'
p4300
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORETHINDRONE'
p4301
sa(dp4302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4303
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4305
sg24
Nsg25
Nsg26
S'Rifampin'
p4306
sg28
Nsg29
S'Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.| \r'
p4307
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p4308
sa(dp4309
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p4310
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4311
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4312
sg24
Nsg25
Nsg26
S'Rifampin'
p4313
sg28
Nsg29
S'Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.| \r'
p4314
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZALEPLON'
p4315
sa(dp4316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p4317
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p4318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4319
sg24
Nsg25
Nsg26
S'Rifampin'
p4320
sg28
Nsg29
S'Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| \r'
p4321
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zebeta'
p4322
sa(dp4323
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p4324
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4325
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4326
sg24
Nsg25
Nsg26
S'Ritalin'
p4327
sg28
Nsg29
S'Ritalin may decrease the hypotensive effect of guanethidine. | \r'
p4328
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GUANETHIDINE'
p4329
sa(dp4330
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p4331
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4332
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4333
sg24
Nsg25
Nsg26
S'Ritalin'
p4334
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4335
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IMIPRAMINE'
p4336
sa(dp4337
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4338
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4339
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4340
sg24
Nsg25
Nsg26
S'Ritalin'
p4341
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4342
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p4343
sa(dp4344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p4345
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4347
sg24
Nsg25
Nsg26
S'Ritalin'
p4348
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4349
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENYLBUTAZONE'
p4350
sa(dp4351
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p4352
sg5
S'http://bio2rdf.org/drugbank:DB00422'
p4353
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4354
sg24
Nsg25
Nsg26
S'Ritalin'
p4355
sg28
Nsg29
S'Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | \r'
p4356
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p4357
sa(dp4358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p4359
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4361
sg24
Nsg25
Nsg26
S'RITONAVIR'
p4362
sg28
Nsg29
S'Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| \r'
p4363
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALMOTRIPTAN'
p4364
sa(dp4365
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p4366
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4367
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4368
sg24
Nsg25
Nsg26
S'RITONAVIR'
p4369
sg28
Nsg29
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p4370
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p4371
sa(dp4372
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p4373
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4374
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4375
sg24
Nsg25
Nsg26
S'RITONAVIR'
p4376
sg28
Nsg29
S'Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | \r'
p4377
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p4378
sa(dp4379
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00625'
p4380
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4381
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4382
sg24
Nsg25
Nsg26
S'RITONAVIR'
p4383
sg28
Nsg29
S'A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| \r'
p4384
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Sustiva'
p4385
sa(dp4386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00862'
p4387
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4389
sg24
Nsg25
Nsg26
S'RITONAVIR'
p4390
sg28
Nsg29
S'Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.| Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.| \r'
p4391
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VARDENAFIL'
p4392
sa(dp4393
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4394
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p4395
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4396
sg24
Nsg25
Nsg26
S'RITONAVIR'
p4397
sg28
Nsg29
S'Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.| \r'
p4398
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p4399
sa(dp4400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00761'
p4401
sg5
S'http://bio2rdf.org/drugbank:DB00986'
p4402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4403
sg24
Nsg25
Nsg26
S'Robinul'
p4404
sg28
Nsg29
S'Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| \r'
p4405
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'POTASSIUM CHLORIDE'
p4406
sa(dp4407
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4408
sg5
S'http://bio2rdf.org/drugbank:DB00296'
p4409
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4410
sg24
Nsg25
Nsg26
S'Ropivacaine'
p4411
sg28
Nsg29
S'In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. | \r'
p4412
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p4413
sa(dp4414
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p4415
sg5
S'http://bio2rdf.org/drugbank:DB00778'
p4416
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4417
sg24
Nsg25
Nsg26
S'Roxithromycin'
p4418
sg28
Nsg29
S'Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. | \r'
p4419
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p4420
sa(dp4421
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4422
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4423
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4424
sg24
Nsg25
Nsg26
S'Sanctura'
p4425
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4426
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4427
sa(dp4428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p4429
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4431
sg24
Nsg25
Nsg26
S'Sanctura'
p4432
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4433
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METFORMIN'
p4434
sa(dp4435
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01337'
p4436
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4437
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4438
sg24
Nsg25
Nsg26
S'Sanctura'
p4439
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4440
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PANCURONIUM'
p4441
sa(dp4442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p4443
sg5
S'http://bio2rdf.org/drugbank:DB00209'
p4444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4445
sg24
Nsg25
Nsg26
S'Sanctura'
p4446
sg28
Nsg29
S'Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | \r'
p4447
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VANCOMYCIN'
p4448
sa(dp4449
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4450
sg5
S'http://bio2rdf.org/drugbank:DB00747'
p4451
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4452
sg24
Nsg25
Nsg26
S'SCOPOLAMINE'
p4453
sg28
Nsg29
S'Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. | \r'
p4454
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p4455
sa(dp4456
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4457
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p4458
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4459
sg24
Nsg25
Nsg26
S'Sensipar'
p4460
sg28
Nsg29
S'Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| \r'
p4461
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4462
sa(dp4463
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4464
sg5
S'http://bio2rdf.org/drugbank:DB01104'
p4465
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4466
sg24
Nsg25
Nsg26
S'SERTRALINE'
p4467
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p4468
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p4469
sa(dp4470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4471
sg5
S'http://bio2rdf.org/drugbank:DB08567'
p4472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4473
sg24
Nsg25
Nsg26
S'SERTRALINE'
p4474
sg28
Nsg29
S'Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | \r'
p4475
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p4476
sa(dp4477
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p4478
sg5
S'http://bio2rdf.org/drugbank:DB00660'
p4479
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4480
sg24
Nsg25
Nsg26
S'Skelaxin'
p4481
sg28
Nsg29
S'SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.| \r'
p4482
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p4483
sa(dp4484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p4485
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p4486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4487
sg24
Nsg25
Nsg26
S'Sonata'
p4488
sg28
Nsg29
S'Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.| \r'
p4489
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'IMIPRAMINE'
p4490
sa(dp4491
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4492
sg5
S'http://bio2rdf.org/drugbank:DB00421'
p4493
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4494
sg24
Nsg25
Nsg26
S'Spironolactone'
p4495
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p4496
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4497
sa(dp4498
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p4499
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4500
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4501
sg24
Nsg25
Nsg26
S'Sprycel'
p4502
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4503
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p4504
sa(dp4505
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4506
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4507
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4508
sg24
Nsg25
Nsg26
S'Sprycel'
p4509
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4510
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4511
sa(dp4512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p4513
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4515
sg24
Nsg25
Nsg26
S'Sprycel'
p4516
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4517
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p4518
sa(dp4519
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4520
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4521
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4522
sg24
Nsg25
Nsg26
S'Sprycel'
p4523
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4524
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p4525
sa(dp4526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4527
sg5
S'http://bio2rdf.org/drugbank:DB01254'
p4528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4529
sg24
Nsg25
Nsg26
S'Sprycel'
p4530
sg28
Nsg29
S'Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| \r'
p4531
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p4532
sa(dp4533
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4534
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p4535
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4536
sg24
Nsg25
Nsg26
S'Stadol NS'
p4537
sg28
Nsg29
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p4538
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p4539
sa(dp4540
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00669'
p4541
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p4542
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4543
sg24
Nsg25
Nsg26
S'Stadol NS'
p4544
sg28
Nsg29
S'When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| \r'
p4545
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUMATRIPTAN'
p4546
sa(dp4547
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p4548
sg5
S'http://bio2rdf.org/drugbank:DB00731'
p4549
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4550
sg24
Nsg25
Nsg26
S'Starlix'
p4551
sg28
Nsg29
S'Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.| \r'
p4552
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p4553
sa(dp4554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00811'
p4555
sg5
S'http://bio2rdf.org/drugbank:DB00649'
p4556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4557
sg24
Nsg25
Nsg26
S'STAVUDINE'
p4558
sg28
Nsg29
S'In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | \r'
p4559
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIBAVIRIN'
p4560
sa(dp4561
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01001'
p4562
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p4563
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4564
sg24
Nsg25
Nsg26
S'Strattera'
p4565
sg28
Nsg29
S'Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| \r'
p4566
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Albuterol'
p4567
sa(dp4568
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p4569
sg5
S'http://bio2rdf.org/drugbank:DB00289'
p4570
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4571
sg24
Nsg25
Nsg26
S'Strattera'
p4572
sg28
Nsg29
S'Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| \r'
p4573
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p4574
sa(dp4575
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p4576
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4577
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4578
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p4579
sg28
Nsg29
S'The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| \r'
p4580
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Brevibloc'
p4581
sa(dp4582
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p4583
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4584
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4585
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p4586
sg28
Nsg29
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p4587
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coly-Mycin M'
p4588
sa(dp4589
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01226'
p4590
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4591
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4592
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p4593
sg28
Nsg29
S'Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. | \r'
p4594
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mivacron'
p4595
sa(dp4596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p4597
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p4598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4599
sg24
Nsg25
Nsg26
S'SUCCINYLCHOLINE'
p4600
sg28
Nsg29
S'Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.| \r'
p4601
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Nimbex'
p4602
sa(dp4603
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p4604
sg5
S'http://bio2rdf.org/drugbank:DB00576'
p4605
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4606
sg24
Nsg25
Nsg26
S'SULFAMETHIZOLE'
p4607
sg28
Nsg29
S'Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p4608
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p4609
sa(dp4610
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p4611
sg5
S'http://bio2rdf.org/drugbank:DB00891'
p4612
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p4613
sg24
Nsg25
Nsg26
S'SULFAPYRIDINE'
p4614
sg28
Nsg29
S'Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| \r'
p4615
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tylenol'
p4616
sa(dp4617
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4618
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p4619
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4620
sg24
Nsg25
Nsg26
S'SULFASALAZINE'
p4621
sg28
Nsg29
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p4622
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4623
sa(dp4624
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00005'
p4625
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p4626
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4627
sg24
Nsg25
Nsg26
S'SULFASALAZINE'
p4628
sg28
Nsg29
S'Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.| \r'
p4629
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Enbrel'
p4630
sa(dp4631
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p4632
sg5
S'http://bio2rdf.org/drugbank:DB01145'
p4633
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4634
sg24
Nsg25
Nsg26
S'SULFOXONE'
p4635
sg28
Nsg29
S'Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. | \r'
p4636
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOLBUTAMIDE'
p4637
sa(dp4638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p4639
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4641
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4642
sg28
Nsg29
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p4643
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'D.H.E. 45'
p4644
sa(dp4645
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00320'
p4646
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4647
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4648
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4649
sg28
Nsg29
S'Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| \r'
p4650
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'D.H.E. 45'
p4651
sa(dp4652
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p4653
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4654
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4655
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4656
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4657
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ESCITALOPRAM'
p4658
sa(dp4659
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p4660
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4661
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4662
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4663
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4664
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p4665
sa(dp4666
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p4667
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4668
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4669
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4670
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4671
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p4672
sa(dp4673
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p4674
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4675
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4676
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4677
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4678
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p4679
sa(dp4680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p4681
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p4682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4683
sg24
Nsg25
Nsg26
S'SUMATRIPTAN'
p4684
sg28
Nsg29
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p4685
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SERTRALINE'
p4686
sa(dp4687
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4688
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p4689
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4690
sg24
Nsg25
Nsg26
S'Sustiva'
p4691
sg28
Nsg29
S'SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.| \r'
p4692
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4693
sa(dp4694
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4695
sg5
S'http://bio2rdf.org/drugbank:DB00625'
p4696
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4697
sg24
Nsg25
Nsg26
S'Sustiva'
p4698
sg28
Nsg29
S'Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.| \r'
p4699
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p4700
sa(dp4701
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p4702
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4703
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4704
sg24
Nsg25
Nsg26
S'Sutent'
p4705
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4706
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p4707
sa(dp4708
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p4709
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4710
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4711
sg24
Nsg25
Nsg26
S'Sutent'
p4712
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4713
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DEXAMETHASONE'
p4714
sa(dp4715
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4716
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4717
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4718
sg24
Nsg25
Nsg26
S'Sutent'
p4719
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4720
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4721
sa(dp4722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p4723
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4725
sg24
Nsg25
Nsg26
S'Sutent'
p4726
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4727
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p4728
sa(dp4729
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4730
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4731
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4732
sg24
Nsg25
Nsg26
S'Sutent'
p4733
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4734
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p4735
sa(dp4736
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4737
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4738
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4739
sg24
Nsg25
Nsg26
S'Sutent'
p4740
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4741
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p4742
sa(dp4743
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p4744
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4745
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4746
sg24
Nsg25
Nsg26
S'Sutent'
p4747
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4748
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p4749
sa(dp4750
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4751
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4752
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4753
sg24
Nsg25
Nsg26
S'Sutent'
p4754
sg28
Nsg29
S'Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | \r'
p4755
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p4756
sa(dp4757
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4758
sg5
S'http://bio2rdf.org/drugbank:DB01268'
p4759
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4760
sg24
Nsg25
Nsg26
S'Sutent'
p4761
sg28
Nsg29
S'Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | \r'
p4762
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p4763
sa(dp4764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p4765
sg5
S'http://bio2rdf.org/drugbank:DB01278'
p4766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4767
sg24
Nsg25
Nsg26
S'Symlin'
p4768
sg28
Nsg29
S'Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). | \r'
p4769
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atropine'
p4770
sa(dp4771
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p4772
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4773
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4774
sg24
Nsg25
Nsg26
S'Tagamet'
p4775
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4776
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CHLORDIAZEPOXIDE'
p4777
sa(dp4778
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p4779
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4780
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4781
sg24
Nsg25
Nsg26
S'Tagamet'
p4782
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4783
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p4784
sa(dp4785
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p4786
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4787
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4788
sg24
Nsg25
Nsg26
S'Tagamet'
p4789
sg28
Nsg29
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p4790
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METRONIDAZOLE'
p4791
sa(dp4792
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p4793
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p4794
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4795
sg24
Nsg25
Nsg26
S'Tagamet'
p4796
sg28
Nsg29
S'However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| \r'
p4797
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Theo-Dur'
p4798
sa(dp4799
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p4800
sg5
S'http://bio2rdf.org/drugbank:DB01195'
p4801
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4802
sg24
Nsg25
Nsg26
S'Tambocor'
p4803
sg28
Nsg29
S'During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| \r'
p4804
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p4805
sa(dp4806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01217'
p4807
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p4808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4809
sg24
Nsg25
Nsg26
S'Tamoxifen'
p4810
sg28
Nsg29
S'Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| \r'
p4811
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ANASTROZOLE'
p4812
sa(dp4813
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p4814
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p4815
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4816
sg24
Nsg25
Nsg26
S'Tamoxifen'
p4817
sg28
Nsg29
S'It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. | \r'
p4818
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PAROXETINE'
p4819
sa(dp4820
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p4821
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4822
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4823
sg24
Nsg25
Nsg26
S'Tarceva'
p4824
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4825
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ATAZANAVIR'
p4826
sa(dp4827
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p4828
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4829
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4830
sg24
Nsg25
Nsg26
S'Tarceva'
p4831
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4832
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p4833
sa(dp4834
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01149'
p4835
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4836
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4837
sg24
Nsg25
Nsg26
S'Tarceva'
p4838
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4839
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NEFAZODONE'
p4840
sa(dp4841
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p4842
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4843
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4844
sg24
Nsg25
Nsg26
S'Tarceva'
p4845
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4846
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NELFINAVIR'
p4847
sa(dp4848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p4849
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4851
sg24
Nsg25
Nsg26
S'Tarceva'
p4852
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4853
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p4854
sa(dp4855
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p4856
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4857
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4858
sg24
Nsg25
Nsg26
S'Tarceva'
p4859
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4860
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tao'
p4861
sa(dp4862
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p4863
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4864
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4865
sg24
Nsg25
Nsg26
S'Tarceva'
p4866
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4867
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TROLEANDOMYCIN'
p4868
sa(dp4869
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p4870
sg5
S'http://bio2rdf.org/drugbank:DB00530'
p4871
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4872
sg24
Nsg25
Nsg26
S'Tarceva'
p4873
sg28
Nsg29
S'Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| \r'
p4874
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VORICONAZOLE'
p4875
sa(dp4876
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p4877
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p4878
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4879
sg24
Nsg25
Nsg26
S'Targretin'
p4880
sg28
Nsg29
S'Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p4881
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GEMFIBROZIL'
p4882
sa(dp4883
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p4884
sg5
S'http://bio2rdf.org/drugbank:DB00857'
p4885
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4886
sg24
Nsg25
Nsg26
S'TERBINAFINE'
p4887
sg28
Nsg29
S'Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | \r'
p4888
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p4889
sa(dp4890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p4891
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4893
sg24
Nsg25
Nsg26
S'TIAGABINE'
p4894
sg28
Nsg29
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p4895
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p4896
sa(dp4897
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p4898
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4899
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4900
sg24
Nsg25
Nsg26
S'TIAGABINE'
p4901
sg28
Nsg29
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p4902
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRIMIDONE'
p4903
sa(dp4904
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p4905
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p4906
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4907
sg24
Nsg25
Nsg26
S'TIAGABINE'
p4908
sg28
Nsg29
S'Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| \r'
p4909
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Valproate'
p4910
sa(dp4911
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p4912
sg5
S'http://bio2rdf.org/drugbank:DB08816'
p4913
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4914
sg24
Nsg25
Nsg26
S'TICAGRELOR'
p4915
sg28
Nsg29
S'The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). | \r'
p4916
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Aspirin'
p4917
sa(dp4918
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p4919
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p4920
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4921
sg24
Nsg25
Nsg26
S'Tikosyn'
p4922
sg28
Nsg29
S'Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| \r'
p4923
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p4924
sa(dp4925
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00742'
p4926
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p4927
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4928
sg24
Nsg25
Nsg26
S'Tobi'
p4929
sg28
Nsg29
S'TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| \r'
p4930
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MANNITOL'
p4931
sa(dp4932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00003'
p4933
sg5
S'http://bio2rdf.org/drugbank:DB00684'
p4934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4935
sg24
Nsg25
Nsg26
S'Tobi'
p4936
sg28
Nsg29
S'In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. | \r'
p4937
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pulmozyme'
p4938
sa(dp4939
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p4940
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p4941
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4942
sg24
Nsg25
Nsg26
S'TOLBUTAMIDE'
p4943
sg28
Nsg29
S'Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| \r'
p4944
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p4945
sa(dp4946
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p4947
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p4948
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4949
sg24
Nsg25
Nsg26
S'TOLBUTAMIDE'
p4950
sg28
Nsg29
S'The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| \r'
p4951
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Atromid-S'
p4952
sa(dp4953
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p4954
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4955
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4956
sg24
Nsg25
Nsg26
S'Toradol'
p4957
sg28
Nsg29
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p4958
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALPRAZOLAM'
p4959
sa(dp4960
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4961
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4962
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4963
sg24
Nsg25
Nsg26
S'Toradol'
p4964
sg28
Nsg29
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p4965
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p4966
sa(dp4967
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p4968
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4969
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4970
sg24
Nsg25
Nsg26
S'Toradol'
p4971
sg28
Nsg29
S'Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| \r'
p4972
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p4973
sa(dp4974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01623'
p4975
sg5
S'http://bio2rdf.org/drugbank:DB00465'
p4976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p4977
sg24
Nsg25
Nsg26
S'Toradol'
p4978
sg28
Nsg29
S'Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| \r'
p4979
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'THIOTHIXENE'
p4980
sa(dp4981
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p4982
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p4983
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4984
sg24
Nsg25
Nsg26
S'Trecator'
p4985
sg28
Nsg29
S'Trecator has been found to temporarily raise serum concentrations of isoniazid.| \r'
p4986
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p4987
sa(dp4988
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00696'
p4989
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p4990
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p4991
sg24
Nsg25
Nsg26
S'Triacetyloleandomycin'
p4992
sg28
Nsg29
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p4993
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ERGOTAMINE'
p4994
sa(dp4995
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p4996
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p4997
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p4998
sg24
Nsg25
Nsg26
S'TRIAMTERENE'
p4999
sg28
Nsg29
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p5000
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p5001
sa(dp5002
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p5003
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p5004
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5005
sg24
Nsg25
Nsg26
S'TRIAMTERENE'
p5006
sg28
Nsg29
S'It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.| \r'
p5007
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Indocin'
p5008
sa(dp5009
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p5010
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p5011
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5012
sg24
Nsg25
Nsg26
S'TRIAMTERENE'
p5013
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p5014
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p5015
sa(dp5016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p5017
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p5018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5019
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p5020
sg28
Nsg29
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p5021
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'APREPITANT'
p5022
sa(dp5023
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p5024
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p5025
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5026
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p5027
sg28
Nsg29
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p5028
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUVOXAMINE'
p5029
sa(dp5030
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p5031
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p5032
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5033
sg24
Nsg25
Nsg26
S'TRIAZOLAM'
p5034
sg28
Nsg29
S'Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| \r'
p5035
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TIAGABINE'
p5036
sa(dp5037
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01023'
p5038
sg5
S'http://bio2rdf.org/drugbank:DB00776'
p5039
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5040
sg24
Nsg25
Nsg26
S'Trileptal'
p5041
sg28
Nsg29
S'Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].| \r'
p5042
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Felodipine'
p5043
sa(dp5044
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00648'
p5045
sg5
S'http://bio2rdf.org/drugbank:DB01108'
p5046
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5047
sg24
Nsg25
Nsg26
S'TRILOSTANE'
p5048
sg28
Nsg29
S'Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).| \r'
p5049
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Mitotane'
p5050
sa(dp5051
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p5052
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5053
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5054
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p5055
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5056
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p5057
sa(dp5058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5059
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5061
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p5062
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5063
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5064
sa(dp5065
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p5066
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5067
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5068
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p5069
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5070
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p5071
sa(dp5072
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5073
sg5
S'http://bio2rdf.org/drugbank:DB01157'
p5074
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5075
sg24
Nsg25
Nsg26
S'TRIMETREXATE'
p5076
sg28
Nsg29
S'Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | \r'
p5077
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p5078
sa(dp5079
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00652'
p5080
sg5
S'http://bio2rdf.org/drugbank:DB00792'
p5081
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5082
sg24
Nsg25
Nsg26
S'TRIPELENNAMINE'
p5083
sg28
Nsg29
S'Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. | \r'
p5084
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Pentazocine'
p5085
sa(dp5086
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p5087
sg5
S'http://bio2rdf.org/drugbank:DB00427'
p5088
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5089
sg24
Nsg25
Nsg26
S'TRIPROLIDINE'
p5090
sg28
Nsg29
S'Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. | \r'
p5091
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Alcohol'
p5092
sa(dp5093
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p5094
sg5
S'http://bio2rdf.org/drugbank:DB01169'
p5095
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5096
sg24
Nsg25
Nsg26
S'Trisenox'
p5097
sg28
Nsg29
S'Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).| \r'
p5098
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p5099
sa(dp5100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5101
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p5102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5103
sg24
Nsg25
Nsg26
S'TROLEANDOMYCIN'
p5104
sg28
Nsg29
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p5105
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5106
sa(dp5107
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p5108
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p5109
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5110
sg24
Nsg25
Nsg26
S'TROLEANDOMYCIN'
p5111
sg28
Nsg29
S'Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | \r'
p5112
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METHYLPREDNISOLONE'
p5113
sa(dp5114
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01111'
p5115
sg5
S'http://bio2rdf.org/drugbank:DB01199'
p5116
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5117
sg24
Nsg25
Nsg26
S'TUBOCURARINE'
p5118
sg28
Nsg29
S'Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| \r'
p5119
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Coly-Mycin M'
p5120
sa(dp5121
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p5122
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5123
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5124
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p5125
sg28
Nsg29
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p5126
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Dextromethorphan'
p5127
sa(dp5128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p5129
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5131
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p5132
sg28
Nsg29
S'Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.| \r'
p5133
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIAZEPAM'
p5134
sa(dp5135
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p5136
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5137
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5138
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p5139
sg28
Nsg29
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p5140
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FLUCONAZOLE'
p5141
sa(dp5142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5143
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p5144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5145
sg24
Nsg25
Nsg26
S'VALDECOXIB'
p5146
sg28
Nsg29
S'Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p5147
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5148
sa(dp5149
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p5150
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5151
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5152
sg24
Nsg25
Nsg26
S'Valproate'
p5153
sg28
Nsg29
S'Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| \r'
p5154
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ISONIAZID'
p5155
sa(dp5156
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00906'
p5157
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5158
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5159
sg24
Nsg25
Nsg26
S'Valproate'
p5160
sg28
Nsg29
S'Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.| \r'
p5161
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TIAGABINE'
p5162
sa(dp5163
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5164
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5165
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5166
sg24
Nsg25
Nsg26
S'VALPROIC ACID'
p5167
sg28
Nsg29
S'Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | \r'
p5168
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p5169
sa(dp5170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p5171
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5173
sg24
Nsg25
Nsg26
S'VALPROIC ACID'
p5174
sg28
Nsg29
S'Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | \r'
p5175
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PHENOBARBITAL'
p5176
sa(dp5177
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00853'
p5178
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p5179
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5180
sg24
Nsg25
Nsg26
S'VALPROIC ACID'
p5181
sg28
Nsg29
S'Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | \r'
p5182
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TEMOZOLOMIDE'
p5183
sa(dp5184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5185
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5187
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p5188
sg28
Nsg29
S'Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.| A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.| \r'
p5189
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5190
sa(dp5191
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p5192
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5193
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5194
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p5195
sg28
Nsg29
S'Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p5196
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p5197
sa(dp5198
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p5199
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5200
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5201
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p5202
sg28
Nsg29
S'Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| \r'
p5203
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RITONAVIR'
p5204
sa(dp5205
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00706'
p5206
sg5
S'http://bio2rdf.org/drugbank:DB00862'
p5207
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5208
sg24
Nsg25
Nsg26
S'VARDENAFIL'
p5209
sg28
Nsg29
S'In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.| Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.| \r'
p5210
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TAMSULOSIN'
p5211
sa(dp5212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p5213
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5215
sg24
Nsg25
Nsg26
S'Verapamil'
p5216
sg28
Nsg29
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p5217
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Adenocard'
p5218
sa(dp5219
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p5220
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5221
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5222
sg24
Nsg25
Nsg26
S'Verapamil'
p5223
sg28
Nsg29
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p5224
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DIGOXIN'
p5225
sa(dp5226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p5227
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5229
sg24
Nsg25
Nsg26
S'Verapamil'
p5230
sg28
Nsg29
S'In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p5231
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'DOFETILIDE'
p5232
sa(dp5233
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p5234
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5235
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5236
sg24
Nsg25
Nsg26
S'Verapamil'
p5237
sg28
Nsg29
S'Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | \r'
p5238
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p5239
sa(dp5240
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00413'
p5241
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5242
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5243
sg24
Nsg25
Nsg26
S'Verapamil'
p5244
sg28
Nsg29
S'Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | \r'
p5245
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PRAMIPEXOLE'
p5246
sa(dp5247
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01195'
p5248
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p5249
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5250
sg24
Nsg25
Nsg26
S'Verapamil'
p5251
sg28
Nsg29
S'Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.| \r'
p5252
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tambocor'
p5253
sa(dp5254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5255
sg5
S'http://bio2rdf.org/drugbank:DB01591'
p5256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5257
sg24
Nsg25
Nsg26
S'Vesicare'
p5258
sg28
Nsg29
S'Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. | \r'
p5259
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5260
sa(dp5261
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p5262
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5263
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5264
sg24
Nsg25
Nsg26
S'Videx'
p5265
sg28
Nsg29
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| \r'
p5266
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CIPROFLOXACIN'
p5267
sa(dp5268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p5269
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5271
sg24
Nsg25
Nsg26
S'Videx'
p5272
sg28
Nsg29
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p5273
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Factive'
p5274
sa(dp5275
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01004'
p5276
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5277
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5278
sg24
Nsg25
Nsg26
S'Videx'
p5279
sg28
Nsg29
S'Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| \r'
p5280
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'GANCICLOVIR'
p5281
sa(dp5282
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p5283
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p5284
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5285
sg24
Nsg25
Nsg26
S'Videx'
p5286
sg28
Nsg29
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p5287
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'NORFLOXACIN'
p5288
sa(dp5289
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5290
sg5
S'http://bio2rdf.org/drugbank:DB00533'
p5291
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5292
sg24
Nsg25
Nsg26
S'Vioxx'
p5293
sg28
Nsg29
S'Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.| \r'
p5294
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p5295
sa(dp5296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p5297
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5299
sg24
Nsg25
Nsg26
S'Viracept'
p5300
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5301
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMIODARONE'
p5302
sa(dp5303
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p5304
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5305
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5306
sg24
Nsg25
Nsg26
S'Viracept'
p5307
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.| \r'
p5308
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ASTEMIZOLE'
p5309
sa(dp5310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p5311
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5313
sg24
Nsg25
Nsg26
S'Viracept'
p5314
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5315
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cisapride'
p5316
sa(dp5317
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p5318
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5319
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5320
sg24
Nsg25
Nsg26
S'Viracept'
p5321
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5322
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'MIDAZOLAM'
p5323
sa(dp5324
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00615'
p5325
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5326
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5327
sg24
Nsg25
Nsg26
S'Viracept'
p5328
sg28
Nsg29
S'Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin| \r'
p5329
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'RIFABUTIN'
p5330
sa(dp5331
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p5332
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5333
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5334
sg24
Nsg25
Nsg26
S'Viracept'
p5335
sg28
Nsg29
S'VIRACEPT and rifampin should not be coadministered.| Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5336
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Rifampin'
p5337
sa(dp5338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p5339
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p5340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5341
sg24
Nsg25
Nsg26
S'Viracept'
p5342
sg28
Nsg29
S'Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| \r'
p5343
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TRIAZOLAM'
p5344
sa(dp5345
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p5346
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5347
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5348
sg24
Nsg25
Nsg26
S'Vistide'
p5349
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5350
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Amikacin'
p5351
sa(dp5352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p5353
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5355
sg24
Nsg25
Nsg26
S'Vistide'
p5356
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5357
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMPHOTERICIN B'
p5358
sa(dp5359
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p5360
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5361
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5362
sg24
Nsg25
Nsg26
S'Vistide'
p5363
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5364
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'FOSCARNET'
p5365
sa(dp5366
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p5367
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5368
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5369
sg24
Nsg25
Nsg26
S'Vistide'
p5370
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5371
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PENTAMIDINE'
p5372
sa(dp5373
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p5374
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5375
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5376
sg24
Nsg25
Nsg26
S'Vistide'
p5377
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5378
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'TOBRAMYCIN'
p5379
sa(dp5380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p5381
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p5382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5383
sg24
Nsg25
Nsg26
S'Vistide'
p5384
sg28
Nsg29
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p5385
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VANCOMYCIN'
p5386
sa(dp5387
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p5388
sg5
S'http://bio2rdf.org/drugbank:DB00152'
p5389
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5390
sg24
Nsg25
Nsg26
S'Vitamin B1'
p5391
sg28
Nsg29
S'Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| \r'
p5392
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p5393
sa(dp5394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p5395
sg5
S'http://bio2rdf.org/drugbank:DB00115'
p5396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5397
sg24
Nsg25
Nsg26
S'Vitamin B12'
p5398
sg28
Nsg29
S'Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.| \r'
p5399
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'AMINOSALICYLIC ACID'
p5400
sa(dp5401
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p5402
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p5403
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5404
sg24
Nsg25
Nsg26
S'Welchol'
p5405
sg28
Nsg29
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p5406
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Calan SR'
p5407
sa(dp5408
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p5409
sg5
S'http://bio2rdf.org/drugbank:DB00930'
p5410
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5411
sg24
Nsg25
Nsg26
S'Welchol'
p5412
sg28
Nsg29
S'WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| \r'
p5413
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p5414
sa(dp5415
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p5416
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p5417
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'int'
p5418
sg24
Nsg25
Nsg26
S'Wellbutrin'
p5419
sg28
Nsg29
S'Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| \r'
p5420
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cyclophosphamide'
p5421
sa(dp5422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p5423
sg5
S'http://bio2rdf.org/drugbank:DB00549'
p5424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5425
sg24
Nsg25
Nsg26
S'ZAFIRLUKAST'
p5426
sg28
Nsg29
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p5427
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Tikosyn'
p5428
sa(dp5429
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01370'
p5430
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5431
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5432
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p5433
sg28
Nsg29
S'The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| \r'
p5434
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ALUMINUM'
p5435
sa(dp5436
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p5437
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5438
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5439
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p5440
sg28
Nsg29
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p5441
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lamivudine'
p5442
sa(dp5443
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00709'
p5444
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5445
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5446
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p5447
sg28
Nsg29
S'Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| \r'
p5448
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Lamivudine'
p5449
sa(dp5450
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01233'
p5451
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5452
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5453
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p5454
sg28
Nsg29
S'Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.| \r'
p5455
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'METOCLOPRAMIDE'
p5456
sa(dp5457
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p5458
sg5
S'http://bio2rdf.org/drugbank:DB00943'
p5459
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5460
sg24
Nsg25
Nsg26
S'ZALCITABINE'
p5461
sg28
Nsg29
S'Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).| \r'
p5462
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'ZDV'
p5463
sa(dp5464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00053'
p5465
sg5
S'http://bio2rdf.org/drugbank:DB00419'
p5466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'mechanism'
p5467
sg24
Nsg25
Nsg26
S'Zavesca'
p5468
sg28
Nsg29
S'While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. | \r'
p5469
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Cerezyme'
p5470
sa(dp5471
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p5472
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p5473
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5474
sg24
Nsg25
Nsg26
S'Zebeta'
p5475
sg28
Nsg29
S'In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| \r'
p5476
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'CLONIDINE'
p5477
sa(dp5478
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p5479
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p5480
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5481
sg24
Nsg25
Nsg26
S'Zebeta'
p5482
sg28
Nsg29
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p5483
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Verapamil'
p5484
sa(dp5485
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p5486
sg5
S'http://bio2rdf.org/drugbank:DB00910'
p5487
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5488
sg24
Nsg25
Nsg26
S'Zemplar'
p5489
sg28
Nsg29
S'Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. | \r'
p5490
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Ketoconazole'
p5491
sa(dp5492
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p5493
sg5
S'http://bio2rdf.org/drugbank:DB00728'
p5494
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5495
sg24
Nsg25
Nsg26
S'Zemuron'
p5496
sg28
Nsg29
S'If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. | \r'
p5497
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'SUCCINYLCHOLINE'
p5498
sa(dp5499
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p5500
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5501
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5502
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p5503
sg28
Nsg29
S'Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| \r'
p5504
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'PROBENECID'
p5505
sa(dp5506
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p5507
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5508
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5509
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p5510
sg28
Nsg29
S'Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. | \r'
p5511
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'STAVUDINE'
p5512
sa(dp5513
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p5514
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5515
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5516
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p5517
sg28
Nsg29
S'A dose adjustment is not needed when zidovudine is administered with VIRACEPT.| \r'
p5518
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Viracept'
p5519
sa(dp5520
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p5521
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p5522
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'advise'
p5523
sg24
Nsg25
Nsg26
S'ZIDOVUDINE'
p5524
sg28
Nsg29
S'Therefore, use of zidovudine in combination with ZERIT should be avoided. | \r'
p5525
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Zerit'
p5526
sa(dp5527
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p5528
sg5
S'http://bio2rdf.org/drugbank:DB02546'
p5529
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5530
sg24
Nsg25
Nsg26
S'Zolinza'
p5531
sg28
Nsg29
S'Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | \r'
p5532
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'VALPROIC ACID'
p5533
sa(dp5534
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01205'
p5535
sg5
S'http://bio2rdf.org/drugbank:DB01198'
p5536
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
S'effect'
p5537
sg24
Nsg25
Nsg26
S'Zopiclone'
p5538
sg28
Nsg29
S'The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.| \r'
p5539
sg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
Nsg37
S'Romazicon'
p5540
sa.